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There would be great value in targeting methylation toward user-defined 
DNA sequences. Directing methylation toward single CpG sites within a 
genome would provide a means to examine the effects of single epigenetic 
alterations on cellular phenotype. The spread, erasure, or maintenance of 
such modifications could be examined in different cellular contexts and 
at different genomic loci. Further, as aberrant methylation patterns 
cause or are implicated in many disease states, targeted methylation 
might be used as a therapeutic.  
 Many groups have attempted to target methylation toward user-
defined sites by fusing a methyltransferase enzyme to a sequence specific 
DNA binding domain. This strategy biases the methyltransferase toward 
specific DNA sequences, but the methyltransferase enzyme is active in 
the absence of the sequence specific DNA binding event. A better strategy 
would involve linking the DNA binding event of sequence specific proteins 
to the activity of the methyltransferase enzyme. 
The contents of this thesis describe work on an assisted protein 
assembly strategy for targeting methylation to single CpG sites within a 
genome. This strategy utilizes naturally or unnaturally bifurcated 
methyltransferases fused to zinc fingers to affect reassembly over a 
desired site. The bifurcated methyltransferases are engineered to have 
reduced affinity for each other and/or for DNA, preventing unassisted 
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enzymatic reassembly at non-targeted CpG sites. Zinc finger binding to 
sequences flanking an internal CpG site increase the local concentration 
of these assembly-deficient, bifurcated methyltransferases, enabling 
enzymatic reassembly and methylation only over the targeted CpG site. 
 In Chapter 2, we demonstrate the successful implementation of 
this strategy for two prokaryotic methyltransferases, M.HhaI and M.SssI. 
Further, we elucidate design parameters important for constructing 
active, targeted, bifurcated methyltransferases. In Chapter 3, we describe 
a novel directed-evolution strategy to quickly identify optimized zinc 
finger-fused bifurcated methyltransferases. Importantly, we also 
demonstrate that substitution of bifurcated methyltransferase fragments 
with new zinc fingers predictably targets methylation toward new zinc 
finger cognate sequences. Finally, in Chapter 4, we describe successful 
preliminary studies in human cell lines. We demonstrate the eukaryotic 
expression of both fragments, targeting specific sites in a mammalian 
expression vector and methyltransferase activity on chromosomal DNA. 
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1 Introduction 
1.1 Biology of methyltransferases 
1.1.1 Discovery of methyltransferases 
The study of DNA methyltransferases is inexorably linked to our 
understanding of molecular biology. In 1959, while studying 
hydroxymethlcytosine incorporation in T-phages, Arthur Kornberg noted 
that “it would be interesting to look for an enzymatic mechanism for 
direct methylation of DNA” in eukaryotic tissues [1]. Then, in 1963, Gold 
and Hurwitz reported partially purified methyltransferases from E. coli 
and showed that they could catalyze methyl transfer onto “acceptor” DNA 
substrates [2,3]. Tying these discoveries together, Werner Arber and 
colleagues showed that phage produced in met- strains, grown in the 
absence of methionine, were not altered by their host [4] and later that 
adenine methylation conferred the host-specific modification protecting 
phage DNA from restriction endonuclease degradation [5,6]. Phage “host-
specificity” is the result of the methyltransferase activity of the host 
during phage replication. Phage DNA produced in these hosts is 
methylated and therefore rendered resistant to host restriction 
endonucleases, whose activity is blocked by methylated DNA. It is now 
known that the biological roles of prokaryotic methyltransferases extend 
beyond the restriction modification (R-M) systems responsible for 
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bacterial phage immunity. Methyltransferases play important roles in 
mismatch repair, cell cycle control, and gene expression [7]). Further, as 
discussed later, groups have challenged the idea that R-M systems 
function exclusively as an innate immunity against phage infection. 
 Analysis of genebank data has identified 4990 putative restriction 
genes and 8080 modification (i.e. methyltransferase) genes [8]. 
Prokaryotic DNA methyltransferases are divided into two broad classes of 
S-adenosylmethionine (SAM) dependent enzymes; the first class 
methylates the C5 position of cytosine and the second class methylates 
the N4 or N6 exocyclic nitrogen of cytosine or adenine respectively (i.e. 
N4mC and N6mA methyltransferases) [9]).  
1.1.2 M.HhaI and M.SssI: Understanding DNA methyltransferase 
structure and function 
M.HhaI is the archetypal prokaryotic cytosine-5-methyltransferase. 
Described in the Hamilton Smith’s Nobel lecture, M.HhaI recognizes and 
methylates the internal cytosine of a four base-pair GCGC site [10]. 
Crystal structures and biochemical studies of this enzyme revealed the 
general architecture and mechanism of all cytosine-5-
methyltransferases. M.HhaI has a bilobal global architecture composed 
of a large and small domain connected by a hinge [11]. The two lobes 
create a cleft that binds DNA.  
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Figure 1.1 Methyltransferase M.HhaI (2HRI) structure and mechanism of 
action [12]. Highly conserved motifs are shown in bright colors, those less 
conserved are shown in light or pale tint colors. Motif I-red; Motif II-light 
orange; Motif III-pale green; Motif-IV-yellow; Motif V-light pink; motif VI-green; 
Motif VII-pale yellow; Motif VIII-cyan; Motif IX-purple; Motif X-blue; target 
recognition (TRD) loops-orange; and DNA-olive [13]. A) Left: Looking at M.HhaI 
with the C-terminal α-helix surrounded by highly conserved motifs I, IV, VI, and 
VIII. B) Right: A view of the methyltransferase looking down the helical axis.  
Note the position of the TRD loops in the major groove and the cytosine residue 
flipped 180° out of the helix and into the active site. C) Bottom: Mechanism of 
action of M.HhaI. 
Based on early sequence alignments and crystal structures, ten 
conserved motifs could be identified (Fig. 1.1 A and B) [11,13,14]. 
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Domains I-V and domain X are involved in SAM binding [9,15]. Domain 
IV also contains the catalytically active cysteine residue. Domains VI and 
VII are involved in binding DNA [9]. Importantly, a relatively non-
conserved, glycine rich portion of the enzyme comprises the target 
recognition domain (TRD) [11].   
Later crystal structures revealed the TRD and active site loop make 
the base-specific contacts with the M.HhaI GCGC recognition site. The 
enzyme bound to its GCGC recognition site induces a “base-flipping” of 
the cytosine out of the DNA helix and into the active site of the enzyme 
(Fig. 1B). Key amino acid residues are shown to stabilize both the 
unpaired guanine and flipped out cytosine [16,17]. 
The enzymatic mechanism of cytosine-5-methyltransferases is 
shown in Figure 1.1C and has been determined by biochemical studies 
[18,19]. Upon flipping of the cytosine into the active site, the active 
cysteine attacks the C6 position of the pyrimidine ring. This results in a 
transient covalent bond between cytosine and the enzyme. It has been 
proposed, for related enzyme M.HaeIII, that protonation of the N3 
facilitates cysteine attack of the C6 and proton removal facilities 
nucleophilic attack from the C5 position onto the methyl group of SAM 
[20]. ß-elimination of the C5 hydrogen and covalently bound cysteine 
restores aromaticity to the ring [21,22]. 
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1.1.2.1 M.SssI: A prokaryotic methyltransferase that recognizes 
all CpG sites 
Like M.HhaI, M.SssI is a prokaryotic CpG methyltransferase. However, 
upon cloning and characterization, it was discovered M.SssI methylates 
all CG sites (unlike M.HhaI which methylates GCGC) [23]. This was 
significant, as it was the first prokaryotic methyltransferase discovered 
with sequence specificity identical to mammalian methyltransferases. 
M.SssI was found to contain the same conserved motifs as M.HhaI and a 
homology model based on M.HhaI crystal structure highlighted many of 
the potential key interactions between M.SssI and DNA; this study also 
revealed that the structure and function of these two enzymes are 
probably very similar [24]. Later mutational studies elucidated important 
residues affecting the catalytic activity and DNA affinity of M.SssI [25,26]. 
1.1.3 Natural evolution  
The conserved domain architecture and mechanistic similarities of 
methyltransferases provides evidence for a common evolutionary 
ancestor. Two, non-mutually exclusive hypotheses: a gene 
duplication/sequence permutation model and a horizontal gene transfer 
model, have been proposed to explain the vast diversity and ubiquitous 
presence of these enzymes in nature. In 1989, Lauster proposed that 
gene duplications events of a common 12-16 Kda ancestor led to the 
initial formation of the major classes of methyltransferases. This was 
based on the observation that adenine and cytosine methyltransferases 
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have homologous blocks of sequences that are repeated intermolecularly, 
and in some cases, intramolecularly [27,28]. Wilson noted that some 
motifs on different methyltransferases were permutated with respect to 
the linear sequence [29]. Malone et al. later identified nine of the ten 
structural motifs in the N6mA and N4mC methyltransferases originally 
identified in the C5-methyltransferases and subsequently classified these 
enzymes by the linear order of their motifs [30].  
 
Figure 1.2 Sequence permutations among prokaryotic CpG 
methyltransferases. An illustration showing how the ten conserved 
methyltransferase motifs can be naturally circularly permuted (M.BssHII) or 
bifurcated (M.AquiI) with respect to M.HhaI (republished with permission from  
[31]). 
Sequence permutation appears to have played a role in the diversification 
of methyltransferases, functioning either by gene duplication followed by 
in-frame fusion, motif shuffling between different methyltransferases or a 
combination of the two [32,33]. Regardless of the mechanism, all classes 
of methyltransferases show some degree of sequence permutation. 
Though rare among C-5-methyltransferases, M.BssHII was shown to be 
circularly permuted (Fig. 1.2) [34]. Further, M.AquiI and M.EcoHK31I 
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were shown to be natural, obligate heterodimers; notably, in both 
methyltransferases, the open reading frames encoding these 
heterodimeric fragments overlap [35-37]. 
 Additionally, horizontal gene transfer has been proposed to explain 
the widespread appearance and diversification of restriction modification 
systems in prokaryotes. Jeltsch et. al. showed a significant correlation 
between the phylogenetic trees constructed of methyltransferases’ innate 
DNA recognition sequences and these enzymes’ amino acid sequences 
[38]. However, these phylogenies did not match the phylogenetic tree of 
bacteria from which the methyltransferases were derived [38-40]. In 
other words, the apparent evolutionary relationships among R-M systems 
appear different than the evolutionary relationships between the species 
containing those systems. Jeltsch further went on to show that the 
codon usage in 29% of endonuclease genes, but to a much lesser extent 
methyltransferase genes, varied significantly from the codon usage of the 
parent organism [40]. This might be explained by the sequential nature 
of the theoretical gene transfer. A prokaryotic organism might first 
acquire a methyltransferase, in order to protect its’ genome, before 
acquiring a potentially toxic restriction endonuclease. The concept of 
domain swapping and mutation to obtain new sequence specificities will 
be discussed in a later section. 
 Kobayashi et. al. proposes that R-M systems may act as selfish, 
mobile genetic elements at odds with the fitness of the organism [41]. 
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This contrasts with the hypothesis of R-M systems evolving as a means 
of beneficial immunity against phage or exogenous genetic elements. 
Among many arguments in this paper, Kobayashi bases this theory on 
the fact that loss of R-M systems often result in loss of cell viability and 
that R-M systems are often associated with mobile genetic elements [41]. 
Both Kobayashi’s theory, along with the phage immunity theory, provide 
explanations for the selective pressures required for the maintenance 
and diversification of methyltransferases. Restriction endonucleases with 
novel substrate specificity will degrade chromosomal DNA unless an 
active methyltransferase is present to methylate DNA and block 
digestion. 
In eukaryotes, there are six subfamilies of DNA methyltransferases 
(Dnmt1-6) [42]. Diversification within these groups most likely results 
from gene duplication events and fusion to other regulatory domains, but 
does not appear to be involved with restriction modification systems [43]. 
Phylogenetic analysis of Dnmt1, Dnmt2 (an RNA methyltransferase), and 
Dnmt3 subfamilies suggests that the three families were present in the 
last common eukaryotic ancestor [42-44]. 
1.1.4 Mammalian methyltransferases 
Cytsosine-5-methyltransferases are the only DNA methyltransferases 
present in eukaryotes. Dnmt1 and Dnmt3 comprise the two families of 
human DNA methyltransferases; the motifs of their catalytic domains 
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show structural homology to M.HhaI [45-47]. Although mechanistically 
similar, the eukaryotic enzymes are fused to other domains responsible 
for protein-protein interactions and regulation, adding additional layers 
of structural and functional complexity relative to their prokaryotic 
counterparts. 
Dnmt1 is responsible for maintenance of methylation due to its 
innate preference for hemimethylated DNA as well as its recruitment to 
DNA during replication and DNA repair [48-51]. Dnmt1 functions as part 
of a large multi-subunit complexes; it localizes to replication foci by 
binding proliferating cellular nuclear antigen (PCNA) [52] and a protein 
known as ubiquitin-like, containing PHD and RING finger domains 1 
(UHRF1) [53]. Additionally, the methyltransferase has been shown to 
interact with multiple other proteins (as reviewed in [54]).  
Dnmt3a and Dnmt3b are the de novo methyltransferases [55,56]. 
Dnmt3a binds to DNA as a heterotetramer, comprised of two Dnmt3a 
enzymes and two molecules of Dnmt3L. Dnmt3L is a catalytically 
inactive protein essential for maintaining proper regulation and activity 
of Dnmt3a and potentially Dnmt3b [46,57-59]. Unlike Dnmt1, Dnmt3a 
and Dnmt3b are highly expressed at different stages in embryonic stem 
cells, but not ubiquitously in most cell types [55,60].  
Dnmt3a and Dnmt3b are also regulated by recruitment to specific 
histone modifications and proteins involved in chromatin remodeling. 
Dnmt3L, Dnmt3a and Dnmt3b were shown to bind specifically to the 
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unmethylated lysine 4 of histone 3 (H3K4) [61-63]. Dnmt3a was shown to 
interact with the histone 3 trimethylated lysine 36 modification 
(H3K36me3) [64]. Additionally, Dnmt3 proteins have been shown to 
interact with the histone methyltransferases and histone associated 
proteins such as G9a (as reviewed [65]). However, these forms of 
transcriptional and spatial regulation do not completely explain how 
methylation patterns are initially established during development.   
1.1.5 Role in mammalian development and disease 
DNA methylation is the most extensively studied epigenetic modification 
in eukaryotic cells and is involved in transcriptional repression. CG 
islands, defined generally as an increase in CpG content at specific 
regions within the genome, are associated with 72% of gene promoters 
[66,67]. In mammals, the erasure of DNA methylation is involved in germ 
cell development and maintenance of stem cell pluripotency. Its 
reestablishment is important for cellular differentiation, maintenance of 
haematopoietic stem cell renewal, centromeric formation, inactivation of 
potentially deleterious repetitive elements, and maintenance of imprinted 
control regions; DNA methylation is influenced and influences histone 
posttranslational modifications and protein-DNA interactions (as 
reviewed in [68]). In many instances it seems that transcriptional 
repressor binding and/or histone posttranslational modification precedes 
methylation. However, methylation may play an important role in 
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stabilizing transcriptional repression and maintaining regions of DNA in 
a heterochromatin state [69]. 
 The importance of DNA methylation on proper development is 
evident from numerous knockout studies. In mice, Dnmt3b knockouts 
result in embryonic lethality and Dnmt3a knockout die shortly after birth 
[56]. Dnmt1 knockouts also result in embryonic lethality [70]. 
Interestingly, embryonic stem cell triple knockout mutants of these three 
enzymes show no signs of chromosomal instability and are capable of 
normal stem cell renewal [71].  
 Aberrant methylation patterns are responsible for numerous 
disease states and are implicated in many more. Imprinting is a 
difference in methylation of maternal and paternal alleles, leading to 
differential allelic expression. Mutation and/or loss of proper imprinting 
causes several diseases such as Prader-Willi and Beckwith-Wiedemann 
syndromes (as reviewed in [72]). Further mutations in Dnmt3b have been 
proposed to lead to immunodeficiency, centromeric instability, and facial 
anomalies (ICF) syndrome [73]. Finally, cancer is characterized by global 
hypomethylation and hypermethylation at CpG islands (as reviewed in 
[69]). 
1.1.5.1  Epigenetic regulation of intercellular adhesion molecule 
1 (ICAM1) in cancer 
ICAM1 is a transmembrane protein that plays a role in trans-endothelial 
cell migration, APC-T-cell communication, and cell signaling (as reviewed 
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in [74]). The role of ICAM1 expression in cancer progression is not 
straightforward and may depend on the cancer type and stage of the 
disease. There is evidence to suggest that increased levels ICAM1 
expression in tumors leads to a better disease outcome. Tumor growth in 
mice was much smaller and showed more leukocyte infiltration if the 
cancer was transfected with an ICAM1 gene prior to injection [75]. Among 
human breast cancer tissues, ICAM1 was negatively correlated with 
tumor size and metastatic potential [76]. Ovarian cancer tissues showed 
decreased expression compared to normal tissue, as assessed by 
immunohistochemistry [77].  
In contrast, there is also evidence suggesting that upregulation of 
ICAM1 facilitates metastasis and tumor growth. The mRNA levels of 
ICAM1 in cancer cell lines positively correlated with metastatic potential 
and siRNA ICAM1 gene suppression lead to a decrease in invasion (as 
assessed by in vitro assays) [78]. ICAM1 expression was also associated 
with metastatic potential in human hepatocellular cancer and expression 
was shown to increase dramatically upon metastasis in mice models [79]. 
High levels of ICAM1 in serum have been associated with increased 
disease potential in numerous cancer lines, presumably by interfering 
with normal immune cell recognition of the membrane bound form of 
ICAM1 [78]. 
Aberrant epigenetic regulation of ICAM1 may explain its altered 
expression in disease states. Treatment of ovarian cancer cell lines with 
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5-aza-2’-deoxycytidine resulted in an increase in expression in all lines 
tested [77]. ICAM1 promoters were shown to be methylated in 70% of 
105 separate bladder cancer tissues removed from patients [80]. 
Hellebrekers et al. showed that ICAM1 transcription in tumor 
conditioned cells could be upregulated by incubation with Dnmt1 and 
HDAC inhibitors [81]. Interestingly, however, no difference in methylation 
was observed before and after incubation with inhibitors. This may be 
representative of the early stages of epigenetic programming, as changes 
in histone modifications were correlated with observed increases in 
expression [81,82]. A similar result was also obtained for highly and 
moderately methylated ovarian cancer cells [83]. Finally, targeted 
demethylation within the ICAM1 promoter was correlated to a 2 fold 
upregulation in gene transcription [84]. 
1.1.6 Biological implications of site-specific CpG methylation 
Though methylation at a single site is not believed to be the main means 
of epigenetic transcriptional silencing, multiple studies suggest single 
methylation events can alter expression levels for select genes. In vitro 
methylation of a single CpG site within the S1000A2 promoter on a 
reporter plasmid resulted in significant downregulation of gene 
expression relative to an unmethylated control [85]. Methylated 
oligonucleotides targeting an intronic region of peroxisomal membrane 
protein 4 (PXMP4 or PMP24) resulted in a single methylation mark on 
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chromosomal DNA that down regulated gene expression relative to 
controls; this corroborated differences observed between normal tissues 
and tumor cells [86]. Electromobility shift assays show that methylation 
at a single site impairs the binding of the global insulator CTCF [87].  
1.2 Engineering of methyltransferases to target altered or user-
defined sequences 
Given the biological importance of DNA methylation and its involvement 
in disease, it would be generally useful to target DNA methylation toward 
user-defined sequences. In addition to studying effects on transcription, 
an engineered methyltransferase that methylates a specific single site in 
a promoter would be generally useful for studying the effects of single 
aberrant methylation events on the propagation, maintenance, and 
correction of epigenetic marks. Finally, methyltransferases were recently 
engineered to more efficiently incorporate the transfer of unnatural alkyl 
groups donated by S-adenosylmethionine cofactor analogues [88]. This 
may make it possible to use targeted methyltransferases in order to site-
specifically label DNA. 
Several groups have used rational design or directed evolution to 
alter both the specificity and activity of methyltransferases. Strategies to 
alter the recognition sequences can be divided into three general 
approaches. The first, I refer to as the mutant methyltransferase strategy. 
This involves mutating important residues in methyltransferases or 
“swapping” domains responsible for targeting methyltransferases to 
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specific DNA sequences. The second strategy, which I refer to as the 
methyltransferase-DNA binding domain fusion strategy, involves fusion of 
a methyltransferase to a sequence specific binding domain. The third, 
which I refer to as an assisted protein complementation strategy, involves 
using zinc finger binding events to aid the assembly of a heterodimeric 
methyltransferase. 
1.2.1 Mutant methyltransferase strategy 
The first strategy involves mutating or exchanging residues involved in 
targeting specific sequences of DNA. As discussed above, the target 
recognition domain (TRD) is a region of poor conservation among various 
methyltransferases and is responsible for most of the residues that make 
sequence specific contacts with DNA. Balganesh et. al. first demonstrated 
that the targeting specificity of fusion methyltransferases was, in part, 
due to a variable “non-conserved region” [89]. The variable or target 
recognition domain of different methyltransferases can be exchanged to 
alter methyltransferase specificity [90-93]. However, this technique often 
greatly reduces or eliminates enzymatic activity. Further, this strategy 
does not allow for the creation of truly new DNA targeting specificities. 
Groups have also used mutation and in vitro selection strategies to relax 
or alter the specificity of methyltransferases. Most selection strategies 
rely on methylation-dependent protection from restriction endonuclease 
digestion to enrich for DNA encoding a methyltransferase with altered 
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specificity [94-98]. Methyltransferases engineered through these 
strategies typically do not have activities and specificities comparable to 
the parent methyltransferase(s). Further, the specificities obtained 
through these methods are usually palindromic and small (≤ 6 base pairs 
in length). Thus, the sequence specificities are too small and limited to 
target specific regions in a genome. 
1.2.2 The methyltransferase DNA binding domain fusion strategy 
Many groups have engineered methyltransferases that bias 
methylation towards user-defined DNA sequences. The general strategy, 
pioneered by Xu and Bestor, involves fusion of a sequence specific DNA 
binding domain (typically a zinc finger protein) to a methyltransferase 
enzyme (Fig. 1.3A) [99]. Interaction between the sequence specific DNA 
binding and its recognition site localizes the fused methyltransferase 
domain to adjacent CpG sites, resulting in biased methylation. These 
constructs have been used to affect methylation, in vitro, in E. coli, and in 
cancer cell lines [100-104]. Biased methyltransferases have been shown 
to stably and heritably reduce the expression of Sox2 and Maspin [105]. 
Siddique et al. demonstrated that targeting methylation towards the 
VEGF-A promoter significantly reduced gene expression in SKOV3 cells 
[106]. A recent review summarizes much of the literature on the creation 
and use of these engineered methyltransferases [107]. 
 17 
 
Figure 1.3 A graphical comparison between the methyltransferase DNA 
binding domain fusion strategy and the assisted protein assembly strategy 
A) A monomeric methyltransferase-zinc finger fusion protein. DNA–zinc finger 
interactions bias the methyltransferase activity toward adjacent CpG sites. B) 
Off-target methylation occurs because the methyltransferase is active even in 
the absence of zinc finger-DNA interactions. C) Both zinc finger-binding events 
at sites flanking a targeted CpG site assist heterodimeric methyltransferase 
reassembly. D) Heterodimeric methyltransferase assembly and activity does not 
occur without zinc finger-DNA interactions.  
 
The limitation of this strategy is that the methyltransferase 
catalytic domain is still active and methylates in the absence of zinc 
finger-DNA interactions (Fig 1.3B). Thus, the methyltransferase fusion 
construct is still able to methylate non-targeted sequences. Most 
engineered methyltransferases methylate multiple CpG sites adjacent to 
the desired target site on the DNA. Despite the successes of these studies 
in biasing methylation to a particular region, little work has focused on 
targeting methylation to single CpG sites [108-110]. 
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1.2.3 Assisted protein assembly strategy 
Our strategy for achieving single-site, targeted methylation is to 
make the assembly of a heterodimeric methyltransferase dependent on 
specific DNA sequences flanking a targeted CpG site (Fig. 1.3C). To 
accomplish this task, our lab has previously employed a natural 
heterodimeric DNA methyltransferase and engineered these heterodimers 
to reduce their ability to reassemble into a functional enzyme [110]. 
Reducing the ability of the fragments to self assemble in a functional 
form is necessary as we and others have shown that bifurcated 
methyltransferases are capable of unassisted reassembly into functional 
enzymes [31,36,37,111,112]. Using these assembly-defective fragments, 
reassembly is then assisted by fusion of the fragments to zinc fingers, 
whose recognition sequences flank the targeted CpG site. The zinc finger 
domains bind to DNA, increasing the local concentration of the fused 
methyltransferase fragments over a targeted CpG site. DNA lacking zinc 
finger binding sites cannot affect functional reassembly, preventing 
methylation at other sites (Fig 1.3D). Previous work in our lab 
demonstrated that optimization of the linker length, C-terminal 
heterodimeric fragment, and target site promotes the functional assembly 
at the targeted CpG site with little observable activity at other sites [110].  
 This strategy is similar to protein complementation strategies first 
demonstrated in the reassembly of dihydrofolate reductase (DHFR). 
Bifurcated versions of this enzyme were shown to reassemble into a 
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functional enzyme only if fragments were fused to homodimerizng and 
heterodimerizing proteins [113]. Reviews of protein complementation 
assays highlight that many enzymes can be altered through bifurcation 
and fusion to dimerizing proteins [114,115]. The Ostermeier lab has 
demonstrated assisted reassembly for bifurcated aminoglycoside 
phosphotransferase (3’)-IIa Neo fused to leucine zippers [116]. Our 
methyltransferase strategy differs, however, because DNA binding 
proteins do not dimerize, but rather complex with adjacent sequences, 
thereby assisting reassembly. 
1.2.3.1 Zinc finger nucleases 
The assisted protein assembly strategy has been used to develop 
zinc finger nucleases (ZFN) and TALE-nucleases (TALENs). The wealth of 
information generated about the function and limitations of ZFNs will 
help to inform later discussions about targeted methyltransferases. Zinc 
finger nucleases were first reported by Kim et. al. Zinc finger nucleases 
are composed of two zinc finger proteins fused to restriction 
endonuclease dimers (typically FokI) [117]. FokI is a type IIs restriction 
endonuclease with modular endonuclease and DNA recognition domains; 
importantly, endonuclease domains were shown to require dimerization 
for activity [118,119]. In a functional ZFN, two zinc finger proteins, each 
fused to a FokI cleaveage domain, recognize two DNA sequences that 
flank a DNA site targeted for digestion. Thus, this strategy directs DNA 
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cleavage to the sites specified by the zinc finger proteins. As discussed 
below, zinc fingers can be designed or evolved to recognize novel 
sequences. In theory, this strategy provides a means to make user-
defined double stranded breaks targeted to any sequence of DNA 
recognized by zinc finger binding proteins. Induction of a double strand 
break followed by non-homologuos end joining (NHEJ) or homologous 
directed repair (HDR) has been used to create genetic knockouts and 
targeted genetic insertions. The technology has been shown to be widely 
successful, targeting numerous genes in a number of model organisms 
including humans (as reviewed in [120]). TALENs, which rely on an 
alternative sequence specific binding protein, induce double strand 
breaks using the same principle and have also successfully also been 
used to affect genetic alterations (as reviewed in [121]). 
In spite of the successful widespread application of this 
technology, zinc finger nuclease technology is still being optimized to 
reduce off-target nuclease activity. Zinc fingers have been shown to be 
cytotoxic and this toxicity is believed to be a result of off-target cleavage 
events [122,123]. Recently, the Liu group was able to use an in vitro 
selection technique to identify large numbers of off-target cleavage events 
catalyzed by these enzymes [124]. Several factors may cause this off-
target cleavage. First, FokI endonucleases can form dimers even if one of 
the proteins lacks a DNA binding domain [119]. ZFN targeting ability may 
not be dependent on both the zinc finger-DNA binding interactions and 
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homodimeric formation may cause off-target cleavage events. Several 
groups have used both structure-guided design and directed evolution 
techniques to reduce the innate ability of FokI to dimerize, reducing 
observed cytoxicity [125-128]. Other research has shown that cytoxicity 
is inversely correlated with the DNA binding specificity of the zinc finger 
domains; this implicates off-target zinc finger binding as a cause of off-
target cleavage events [129]. Finally results in cancer cell lines indicated 
that the linkers connecting zinc fingers to FokI domains, as well as the 
spacer length separating zinc finger binding sites greatly affect ZFN 
selectivity [130]. The combined results of these studies demonstrate that 
a number of factors will affect the specificity and activity of assisted 
protein assembly strategies based on obligate heterodimeric-zinc finger 
fusions proteins. 
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1.2.3.2 Design of zinc fingers with novel DNA binding   
specificities 
 
Figure 1.4 Crystal structure and key binding interactions of Zif268 with 
DNA A) Crystal structure ,1AAY, of DNA (grey) bound by zinc finger 268 (blue). 
The alpha helices sit in the major groove enabling residues to make base-
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specific contacts, here shown as sticks (orange). B) Diagram outlining all 
residues in zinc finger 268 that make sequence specific contact with DNA 
(republished with permission from [131]). 
Zinc fingers were first identified as a repetitive protein motif in Xenopus 
oocytes. Each motif was found to contain two conserved histidine and 
cysteine residues coordinated to zinc [132]. There are now known to be 
many other types of zinc fingers, classified by the composition of the four 
amino acids responsible for coordinating zinc (as reviewed in [133]). The 
discussion here will be restricted to a specific class of canonical C2H2 
zinc fingers that are used in most of the described engineering studies 
mentioned. Pabo’s group solved the crystal structure of murine zinc 
finger 268, revealing many of the general structural features of these 
proteins (Fig. 1.4A and B). Zinc fingers are comprised of multiple motifs, 
each containing two beta sheets, antiparallel to one another, and an 
alpha helix. This motif structure is stabilized by contacts between 
hydrophobic residues as well as a coordinated zinc ion [134]. The alpha 
helix sits within the major groove of DNA and mediates almost all of the 
base-specific contacts with one strand of DNA. Each zinc finger motif 
recognizes three bases of DNA. However, residues often contact the bases 
immediately preceding this three base sequence and each motif may not 
make contacts with all three bases. The zinc finger binds the three bases 
of DNA in an ‘antiparallel’ orientation [131,134]. 
The periodic nature and regular structure of zinc finger binding 
proteins has encouraged many groups to design zinc fingers that bind to 
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new sequences. Theoretically, any sequence of DNA could be targeted if 
zinc finger motifs were completely modular and if motifs could be 
identified that recognize each of the 64 possible three-base pair 
combinations. Pabo et al. reviews work attempting to create ‘rules’ 
linking zinc finger protein sequence with DNA binding specificity. He 
concludes that although the protein motif is fairly well conserved, 
individual zinc finger residue/DNA interactions are not always regular 
and therefore predictable [135].  
Directed evolution techniques have provided a more tractable and 
successful approach for designing new zinc finger motifs that bind novel 
sequences. One widely used technique involves creating fusions between 
randomized zinc finger proteins and the pIII protein of filamentous 
phage. Expression of these fusion constructs and affinity purification of 
phage, using novel DNA sequences bound to a solid support, identifies 
zinc finger motifs with novel sequence specificity [136-138]. This strategy 
is most successful when one motif of the three-finger protein is modified 
at a time. Using phage selections, motifs have been selected that 
recognize 49 of the possible 64 three base pair combinations [139-143]. 
Available lab programs identify motifs based on input DNA sequences, 
allowing for facile design of zinc fingers with new DNA binding 
specificities [144,145]. However, as assessed by a bacterial two-hybrid 
system, 76% of zinc finger proteins created by assembling previously-
selected zinc finger motifs fail to bind their predicted sites [146]. 
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One possible explanation for this observation is that zinc finger 
motif-DNA interactions are not completely modular, but are instead 
partly context dependent upon surrounding motifs [147]. To address 
this, the Joung lab has used several strategies, combining DNA shuffling 
and bacterial two-hybrid selections to identify 3-motif zinc fingers that 
recognize DNA in vivo [148-150]. These strategies may be more effective 
at generating functional and specific zinc fingers for in vivo applications. 
Computer programs such as context dependent assembly (CoDA) allow 
for in silico design by combining two-motifs units known to function 
together. Designing zinc fingers with the context dependent assembly 
strategy has a greater reported success rate than modular assembly 
strategies [151]. 
In spite of the successful application and creation of zinc fingers 
with novel DNA specificities, there are still limitations to zinc finger 
design. As discussed above, high levels of off-target activity have been 
observed for zinc finger-fusion proteins and 15 of the 64 possible three 
nucleotide DNA binding motifs have yet to be identified. The recent 
elucidation and use of sequence specific transcription activator-like 
effectors (TALEs) have proven a promising alternative to zinc fingers. The 
discovery that a single repeated motif recognizes a single DNA base may 
make these proteins more modular and less context dependent on 
surrounding motifs than zinc fingers [152,153]. The discovery of two 
divariable residues capable of conferring base-protein recognition 
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enabled the construction of TALEs with predictably altered specificities 
[154]. 
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Intended to be blank 
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2 Targeting DNA methylation using and artificially 
bisected M.HhaI fused to zinc fingers 
2.1 Introduction 
Many groups have biased methylation to specific DNA sequences by 
fusing methyltransferase enzymes to sequence-specific DNA binding 
proteins [99-101,103,155,156]. However, these fusion proteins still 
methylate away from the desired DNA sequence. This off-target activity 
occurs because the methyltransferase remains functional in the absence 
of the DNA-binding protein’s association with its cognate DNA sequence. 
To reduce off-target activity, methyltransferase fusion proteins have been 
engineered with reduced overall activity, so that a bias in methylation 
can be observed. However, reducing enzyme activity does not address the 
fundamental limitation of this strategy, and these fusion constructs still 
methylate at non-targeted sites. Furthermore, many of these studies 
assess the level of specificity and activity in eukaryotic cells, which 
contain endogenous CpG methyltransferases. This therefore limits the 
ability to conclusively determine the true specificity and activity of these 
enzymes in vivo. A better strategy would make methyltransferase activity 
contingent upon association of the DNA binding domain with its target 
DNA sequence. Characterization of these enzymes in E. coli, which lack 
CpG methyltransferases, rather than eukaryotic cells, will allow for the 
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unambiguous characterization of enzymatic activity and specificity in 
vivo. 
Our strategy for designing targeted methyltransferases couples the 
methyltransferase activity to the DNA binding protein’s association with 
DNA. A monomeric methyltransferase is split into two fragments that are 
compromised in their ability to assemble into an active heterodimeric 
enzyme, and each fragment is fused to a different zinc finger. The zinc 
fingers’ DNA binding sites flank a desired CpG site. Thus, zinc finger 
binding to cognate DNA sites increases the local concentration of the two 
attached methyltransferase fragments, encouraging the fragments to 
reassemble only over a desired CpG site. The association of the two 
fragments into an active enzyme in the absence of the flanking zinc finger 
binding sites is limited because the two fragments are engineered to have 
reduced affinity for one another or require each other for proper folding. 
In this manner, the strategy is akin to a assisted protein assembly or 
protein complementation assay [157] with a specific DNA sequence 
mediating assembly of the active methyltransferase. 
The Ostermeier laboratory has previously demonstrated this 
strategy using the naturally split methyltransferase M.EcoHK31I, which 
methylates the internal cytosine of the 5′-YGGCCR-3′ site. We 
demonstrated how reduction of the fragment’s affinity for each other 
through truncation of one of the fragments increased the ratio of 
methylation at the target vs. non-target sites. The optimized construct 
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exhibited (>50%) methylation at the target site and undetectable 
methylation at the non-target site under the correct expression 
conditions [110]. However, off-target methylation could be observed 
under different expression conditions. Furthermore, the M.EcoHK31I 
targeted cytosine residue is not a CpG site, and therefore would not be 
applicable for CpG methylation studies in mammalian cells.  
Here we demonstrate our strategy using an artificially split 
M.HhaI, a CpG methyltransferase derived from M.HhaI fragments 
previously identified in our lab [31]. Using modeling and 
experimentation, we show how proper geometric configuration of the 
M.HhaI fragments and the zinc fingers is important for the bias and 
activity observed at the target site. With the proper fusion configuration 
of M.HhaI fragments and zinc finger proteins, we show how bias towards 
the target site can be increased through mutations rationally designed to 
reduce the association of the two fragments, through optimization of the 
linkers connecting the M.HhaI fragments to the zinc fingers, and through 
optimization of the distance between the zinc finger binding sites and the 
targeted methylation site. Optimization resulted in an engineered 
methyltransferase that methylated 50-60% of a desired the target site in 
E. coli cells with minimal levels of methylation at a non-target M.HhaI 
site.    
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2.2 Materials and methods 
2.2.1 Modeling  
The structural model for M.HhaI methyltransferase was obtained from 
the crystal structure of the M.HhaI/DNA complex (PDB 2HR1) [12]. For 
target DNA sequences, straight B-DNA structures containing all the three 
binding sites (one M.HhaI target site and two zinc-finger binding sites) 
were built using the model.it web server [158]. 
For zinc fingers HS1 and HS2, homology models were constructed 
using the Rosetta comparative modeling algorithm employing zinc finger 
Zif268 (1AAY) as the template [131,159]. Comparative modeling involves 
1) copying coordinates from regions aligned with the template sequence, 
2) a centroid pseudo-atom side-chain low-resolution building of the 
unaligned regions using a fragment based loop modeling protocol [160], 
and 3) a final all-atom high-resolution phase refinement with small 
backbone perturbations followed by gradient-based minimization and 
side-chain packing. One thousand models were generated for each of the 
zinc fingers and the top ranked structures based on the Rosetta standard 
energy function were selected. Kinks were observed in the C-terminal α-
helices when these zinc finger models were superimposed on the 
template structure, as zinc atoms were not included during modeling. 
These kinks were fixed by threading the backbone of α-helices over the 
corresponding C-terminal α-helix from the template structure.  
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The final complex including zinc fingers and M.HhaI bound to the 
respective target sites was then assembled. The orientation of the zinc-
fingers and M.HhaI at their respective binding sites was determined by 
aligning target DNA sequences from M.HhaI/DNA complex (2HR1) and 
Zif268/DNA complex (1AAY) with the straight B-DNA model.  
Finally, the linker regions connecting the N-terminal and C-
terminal fragments of M.HhaI to the zinc fingers were built using Rosetta 
kinematic closure (KIC) loop modeling algorithm [161]. The algorithm 
couples KIC calculations with 1) a low-resolution stage involving loop 
backbone minimization with side chains represented as centroids, and 2) 
an all-atom high-resolution stage with Monte Carlo-plus-minimization of 
side-chain and loop backbone dihedral angles. The calculations in the 
paper were carried out using Rosetta’s developer revision number 46351. 
All algorithms are also available in Rosetta’s release version 3.4. The 
Rosetta command-line arguments and scores used for the calculations 
are as follows. 
(a) Modeling the zinc fingers 
minirosetta.<exe> –database <path_to_rosetta_database>  


















where 1AAY.pdb is the template structure and 1hs1_.aln is the 
sequence alignment of target and template 
(b) Constructing the linker regions (loop building) 
loopmodel.<exe> –database <path_to_rosetta_database>  
–loops:input_pdb fnl1.pdb 
–loops:loop_file fnl1.loop   
–loops:remodel perturb_kic  





where fnl1.pdb is the input PDB and fnl1.loop defines the range of loop 
residues 
2.2.2 General methods, reagents, and bacterial strains 
Restriction enzymes, T4 ligase, and M.HhaI were purchased from New 
England Biolabs (Ipswich, MA, USA) and were used according to 
manufacturers instructions. Oligos were purchased from Invitrogen 
(Carlsbad, CA, USA) and Integrated DNA Technologies (Coralville, IA, 
USA). Platinum® Pfx DNA Polymerase was purchased from Invitrogen 
(Carlsbad, CA, USA). dNTPs were purchased from Thermo scientific 
(Rockford, IL, USA). Agarose gel electrophoresis and PCR were preformed 
essentially as described previously [162].  Escherichia coli K-12 strain 
ER2267 [F´ proA+B+ lacIq Δ(lacZ)M15 zzf::mini-Tn10 (KanR)/ Δ(argF-
lacZ)U169glnV44 e14-(McrA-) rfbD1? recA1 relA1? endA1 spoT1? thi-1 
Δ(mcrC-mrr)114::IS10] was acquired from New England Biolabs (Ipswich, 
MA, USA) and was used for cloning and methylation protection assays.  
2.2.3 Plasmid and gene construction and design 
Plasmid pDIMN8 was derived from pDIMN7 MeND/MeCD [109]. An FspI 
restriction site was silently mutated within AmpR. Zinc finger genes were 
fused to M.HhaI methyltransferase gene fragments via desired length 
linkers using overlap extension PCR. Test sites for methylation (site 1 
and site 2) were designed with an internal M.HhaI recognition site (5’-
GCGC-3’) nested within an FspI restriction site (5’-TGCGCA-3’). These 
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sites were flanked on either side by HS1 and HS2 zinc finger binding 
sites [163] or control DNA sequences as desired. Zinc finger recognition 
sites were separated from the FspI restriction site by 0, 1, 2 or 3 bp.   
To facilitate changing the DNA sequences at these sites, site 1 was 
flanked by XmaI and EcoRI restriction sites and site 2 was flanked by 
AflIII and BglII sites. The BglII site was created by inserting three bp 66 
base pairs downstream from the ColE1 origin of replication. The DNA at 
sites 1 and 2 were altered by annealing complimentary oligonucleotides 
encoding the desired DNA sequences. The oligonucleotides were designed 
such that the annealed product possessed overhangs that complemented 
the restriction site overhangs produced by digestion at the flanking 
restriction enzyme sites. Phosphorylation of the annealed 
oligonucleotides followed by ligation into digested vectors was used to 
change the sequence at sites 1 and 2. 
2.2.4 Methylation protection assays and quantification. 
In vivo protection assays were preformed in E. coli strain ER2267. Frozen 
stocks were prepared by inoculating 10 mL of lysogeny broth, 
supplemented with 100 μg/μl ampicillin and 0.2% w/v glucose, with cells 
from a single colony. After 12-16 hrs of incubation at 37˚ C, 800 μl of cell 
culture was mixed with 200 μl of 50% v/v glycerol to create glycerol 
stocks, which were stored at -80°C.   
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To perform methylation assays, 5 μl of thawed glycerol stocks were 
used to inoculate 10 ml of lysogeny broth supplemented with 100 μg/μl 
ampicillin salt. To repress the lac promoter, 0.2% w/v glucose was 
added. To induce the lac and pBAD promoters, cultures were 
supplemented with 1.0 mM of IPTG and 0.0167% w/v arabinose, 
respectively. Experiments carried out to optimize methylation indicated 
that inoculation into media containing glucose, IPTG, and arabinose 
resulted in the highest levels of observed methylation activity. Thus, 
cultures contained 0.2% glucose, 1.0 mM of IPTG and 0.0167% w/v 
arabinose unless otherwise indicated. After 12-14 hours of incubation at 
250 rpm and 37˚ C, plasmid DNA was isolated from the cells using 
QIAprep Spin Miniprep Kit (Qiagen, Valencia, CA). 
To ascertain the methylation status at sites 1 and 2 of the plasmid, 
plasmid DNA (500 ng) was incubated with 2.5 units of FspI and 10 units 
of NcoI-HF in buffer NEB4 at 37˚ C for 2 hours. After digestion, the DNA 
was electrophoresed in a 1.2% w/v agarose gel in TAE buffer at 90 V for 
80 minutes at room temperature. Images were captured using the 
Molecular Imager XRS Gel Doc system with Quantity One software. 
To quantify the percentage of plasmids methylated at each site, 
plasmid DNA (500 ng) was digested with 10 units of NcoI-HF and 2.5 
units of FspI in buffer NEB4 at 37˚ C for 2 hours and half of each 
digested sample (250 ng) was electrophoresed in a 1.2% w/v gel for 2 
hours at 90 V. Images were captured using the Gel Logic 112 Imaging 
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System. The intensities of each of the four largest bands were determined 
using Carestream Molecular Imaging Software and corrected to be on a 
mol basis using the expected length of each DNA fragment. Percentages 
of methylation are based on the intensity of a given band relative to the 
total intensity in the lane. Each construct was tested using ≥3 
independent cultures. The mean percentage is reported and the error bar 
represents the standard deviation (n≥3).   
2.2.5 Bisulfite sequencing 
Unmethylated pDIMN8 plasmid was obtained by inoculating cells in 10 
mL of lysogeny broth under conditions that repress gene expression, as 
described above. Methylated controls were obtained by incubating 8 μg of 
the unmethylated plasmid at 37°C for 1 hour with 50 units of M.HhaI 
(New England Biolabs, Ipswich, MA, USA) in 1X HhaI methylase reaction 
buffer supplemented with 32 mM S-adenosylmethionine. DNA was 
purified using the Zymo Clean and Concentrator kit according to 
manufacturers instructions (Zymo Research Corporation, Irvine, CA, 
USA).   
  For the experimental samples, ER2267 cells containing pDIMN8 
plasmids encoding for methyltransferase fragments, were grown under 
conditions that induce expression, in triplicate, as described above. DNA 
was isolated from cells using QIAprep Spin Miniprep Kit and digested 
with 20-40 units of NcoI at 37˚ C for 1-2 hours (Qiagen, Valencia, CA). 
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Linearized DNA was purified using the Zymo Clean and Concentrator-5 
kit according to manufacturers instructions. DNA was then treated with 
bisulfite reagent and purified using the EZ DNA Methylation-Gold Kit 
according to manufacturers instructions (Zymo Research Corporation, 
Irvine, CA, USA). Individual strands from site 1 and site 2 were then 
amplified with a set of unique primers, using One Taq Hot Start DNA 
Polymerase (New England Biolabs, Ipswich, MA, USA). PCR amplified 
DNA was purified using the Zymo Clean and Concentrator kit. Purified, 
PCR amplified DNA, 10 ng, was directly sequenced by Genewiz (South 
Plainfield, NJ, USA). The heights of trace files in Figure 2.6 were adjusted 
to aid in direct comparison. 
2.2.6 HhaI restriction assay 
To ascertain the total methylation status of all 36 HhaI recognition sites, 
ER2267 cells containing methyltransferase fusion constructs were used 
to inoculate 10 mL of lysogeny broth medium supplemented with 100 
μg/mL ampicillin salt. Cells were inoculated in conditions shown to 
repress or induce methyltransferase gene expression (0.2% w/v glucose 
for gene repression or 0.2% glucose, 1.0 mM of IPTG and 0.0167% w/v 
arabinose for gene induction). After 12-14 hours of incubation at 250 
rpm and 37˚ C, plasmid DNA was isolated from the cells using QIAprep 
spin miniprep kit (Qiagen, Valencia, CA, USA). 
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 Plasmid DNA (500 ng) was incubated with 10 units of HhaI in 1X 
NEB4 and 1 μg/mL BSA at 37˚ C for 2 hours. After digestion, the DNA 
was electrophoresed in a 2.5% w/v agarose gel in TAE buffer at 90 V for 
50 minutes at room temperature. Images were captured using the 
Molecular Imager XRS Gel Doc system with Quantity One software. 
2.2.7 Chromosomal restriction assay 
ER2267 cells containing variants with X=3, Y=1, and Z=0, a C-terminal 
truncation of 6 or 4 amino acids, and zinc finger binding sequences at 
site 1, were grown under conditions known to induce or repress 
expression of the heterodimeric methyltransferase (see Materials and 
Methods). Chromosomal DNA was isolated using the Sigma’s GenElute 
Bacterial Genomic Kit according to the manufacturer’s instructions 
(Sigma-Aldrich, St. Louis, Missouri , USA). Chromosomal DNA was 
electrophoresed on a 0.8% w/v agarose gel in TAE buffer at 90V for 35 
min. to separate genomic DNA from plasmid DNA. Chromosomal DNA 
was isolated from the gel and purified using Invitrogen’s PureLink Quick 
Gel Extraction Kit (Invitrogen Carlsbad, CA, USA). DNA was further 
purified by ethanol precipitation as described in Sambrook and Russel 
[162]. The global level of methylation on the chromosome was assessed 
by incubating 250 ng of DNA with 5 U of FspI in 1X NEB4 for 1 hr at 
37°C. A methylated control was prepared by incubating 250 ng of 
chromosomal DNA at 37°C for 1 hour with 12.5 U of M.HhaI in 1X HhaI 
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methylase reaction buffer and 80 μM S-adenosyl-methionine, heat killing 
the reaction at 65°C for 20 minutes and then incubating the reaction 
with 5 U of FspI in 1X NEB4 for 1 hr at 37°C. (New England Biolabs, 
Ipswich, MA, USA).  DNA was electrophoresed on a 1% w/v agarose gel in 
TAE at 90V for 70 minutes. Images were captured using the Molecular 
Imager XRS Gel Doc system with Quantity One software. 
2.3 Results and discussion 
Our group previously identified two M.HhaI fragments that could 
assemble into a functional methyltransferase enzyme in an unassisted 
fashion [31]. The N-terminal fragment is comprised of amino acids 
M.HhaI[1-240], and the C-terminal fragment is composed of amino acids 
M.HhaI[210-326]. Each fragment shared a common internal 30 amino 
acids, M.HhaI[210-240], referred to as the overlapping region. This 
overlapping region is analogous to the region where some natural 
methyltransferases are split or circularly permuted [33].  
Nomura and Barbas reported that fusion of one zinc finger to the 
N-terminus of M.HhaI[1-240] and a second zinc finger to the C-terminus 
of M.HhaI[210-240] resulted in a targeted methyltransferase [108]. 
However, our analysis of their engineered enzyme using more definitive 
assays showed that it methylates target and non-target sites with the 
same low efficiency [109]. Nevertheless, we imagined that our fragments 
might be converted to a targeted methyltransferase if we (1) fused the 
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fragments to zinc fingers in the correct orientation relative to the target 
DNA sequence, (2) reduced the fragments ability to assemble in an 
unassisted fashion through mutations designed to reduce the fragments’ 
affinity for each other, (3) optimized the linkers connecting the fragments 
to the zinc fingers, and (4) optimized the number of bases separating the 
zinc finger binding sites from the M.HhaI recognition site.  
2.3.1 Initial studies   
In principle, each methyltransferase fragment could be fused to a zinc 
finger at the fragment’s N- or C-terminus (Fig. 2.1A); combining these 
fusion variants creates four distinct zinc finger/methyltransferase 
fragment fusion topologies. We have previously shown that a particular 
ZN/CZ fusion pair (see Fig. 2.1A for nomenclature) designed by Nomura 
and Barbas [108] exhibits low-level, non-specific methylation of M.HhaI 
DNA sites in vivo [109]. In contrast, our initial tests of the NZ/ZC fusion 
pair displayed some bias towards a target flanked by the zinc finger 
binding sites.   
 We next desired to model all four combinations of fusion pairs to 
predict the optimal combination for fragment reassembly at the target 
site and to estimate the linker lengths that would be required to connect 
the zinc finger and the methyltransferase fragments. However, the 
presence of the 30 amino acid overlapping region on both fragments 
complicated the modeling. We wondered if this region could be removed 
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from one of the two fragments without compromising activity. Using the 
NZ/ZC construct, we conducted a set of experiments designed to probe 
the importance of the common 30 amino acids present in both the N-
terminal fragment and C-terminal fragment. These experiments revealed 
that when the fragments are fused to zinc fingers, the 30 amino acids 
could be removed from the N-terminal fragment (but not from the C-
terminal fragment) without reducing methyltransferase activity. The 
fragment pair M.HhaI[1-209] and M.HhaI[210-326], which lacks any 





Figure 2.1 Schematic depictions of sequences and nomenclature of 
modeled protein/DNA complexes (A) Sequences of zinc fingers fused to 
fragments of M.HhaI methyltransferase.  Numbers in brackets correspond to 
the amino acid numbers. Black segments correspond to linker sequences. (B) 
The orientation of the zinc finger binding sites relative to the intended 
methylation target site (the circle). The orientations depicted are the ones that 
would position the indicated protein pairs over the targeted CpG site. (C) 
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Molecular model of a particular NZ/CZ construct containing the indicated 
linkers. The base to be methylated is indicated in purple. Models of all 
complexes without linkers can be found in Figure 2.2. Krishna Praneeth 
Kilambi created the pymol model used to make this image. 
2.3.2 In silico modeling illustrates the spatial constraints of a 
functional M.HhaI heterodimeric/zinc finger fusion protein 
with targeted activity 
We used in silico modeling to predict the structures of the four possible 
combinations of M.HhaI fragments and zinc fingers bound to DNA. Each 
of the four pairs of fusion combinations required a particular placement 
of the zinc finger binding sites relative to the internal CpG site (Fig. 
2.1B). Other orientations of the zinc finger binding sites relative to the 
internal CpG site would present one or both methyltransferase fragments 
away from this targeted cytosine. For each of the four configurations 
depicted in Figure 2.1B, we produced two models in which the 
methyltransferase was positioned to methylate either the top or the 
bottom strand relative to the bound zinc fingers (Fig. 2.2). Modeling 
assumed straight B-DNA structure and thus does not capture any 
distortions of the DNA that may or may not be induced by the binding of 
the fusion proteins to DNA. 
Modeling predicted that fusion of the zinc fingers to the fragments 
at the bisection site (i.e. configuration NZ/ZC) would best position the 
fragments in an orientation capable of reassembling and therefore 
methylating a targeted CpG site (Fig. 2.1C). We judged this pair as 
optimal because it required the shortest linkers connecting the zinc 
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fingers to the methyltransferase fragments. All configurations other than 
NZ/ZC required linkers that would need to circumvent long distances 
around the DNA or methyltransferase domains and connect residues 
separated by at least 40 Å (Fig. 2.2). Although one could conceivably use 
very long, flexible linkers to traverse these long distances, we reasoned 
that such constructs would do a poorer job of increasing the local 
concentration of the two fragments at the target site. 
The NZ/ZC model indicated that the linker connecting the N-
terminal fragment and its respective zinc finger would need to be longer 
than that connecting the C-terminal fragment and its zinc finger. The 
models were consistent with our initial experimental results and provided 
a rationale for why the NZ/ZC fusion pair, but not the ZN/CZ pair, 
exhibited some bias for methylating the target site. The models also 
supported our hypothesis that methylation could be biased towards a 
target site via a DNA-targeted reassembly method that works by 




Figure 2.2 Models for four possible fusion combinations of M.HhaI 
fragments and zinc fingers bound to DNA. Continued on next page. 
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Figure 2.2 continued. Models for four possible fusion combinations of 
M.HhaI fragments and zinc fingers bound to DNA. For each of the four 
configurations, models were constructed with the methyltransferase positioned 
to bind the top or the bottom strand relative to the bound zinc fingers (columns 
1 and 2). The ‘X’ and ‘Y’ labels indicate the location of the zinc finger and 
methyltransferase termini that need to be connected via a peptide linker in 
order for the zinc finger and M.HhaI domains to be bound to DNA as labeled. 
The ‘X’ label present on zinc finger HS1 termini should be fused to the ‘X’ label 
on the termini of M.HhaI [1–209]. The ‘Y’ label present on zinc finger HS2 
termini should be fused to the ‘Y’ label on M.HhaI [210–326]. Krishna Praneeth 
Kilambi created the pymol models used to construct this image. 
2.3.3 Plasmid and restriction enzyme protection assay design 
We placed the genes encoding the NZ/ZC fragment pairs in a plasmid 
under separate inducible promoters (Fig. 2.3A). These genes also encoded 
different length peptide linkers connecting the zinc fingers and the 
methyltransferase fragments. For assessing methylation levels, the 
plasmid also contained two M.HhaI test sites (5’-GCGC-3’) that were 
nested within FspI sites (5’-TGCGCA-3’). FspI digestion is blocked by 5mC 
methylation at the first cytosine in the recognition sequence [164]. The 
plasmid also contained a unique NcoI site, so that linearization by NcoI, 
along with incubation with FspI and agarose gel electrophoresis could be 
used to distinguish between the four possible methylation states of these 
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two sites (Fig. 2.3 B and C). The two test sites were flanked by HS1 and 
HS2 zinc finger binding sites (Fig. 2.3 D), control sequences (Fig. 2.3 E), 
or combinations thereof. Various length spacer nucleotides separated the 
FspI site and these sequences. The in vivo methyltransferase activity 
assay was preformed by culturing ER2267 cells containing these 
plasmids in the presence or absence of the inducers for 
methyltransferase fragment expression.  
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Figure 2.3 A schematic of the restriction enzyme protection assay for 
targeted methylation  (A) A single plasmid, pDIMN8, encodes genes for both 
methyltransferase fragment-zinc finger fusion proteins, as well as two sites for 
assessing the degree of targeted methyltransferase activity.  Expression of both 
protein fragments was induced in ER2267 cells and plasmid DNA was isolated. 
(B) Plasmid DNA was linearized by NcoI-HF digestion and incubated with FspI, 
an endonuclease whose activity is blocked by methylation. In the absence of 
methylation, the plasmid is digested twice by FspI and once by NcoI-HF as 
shown. (C) Methylation at one or both of the FspI containing sites creates 
unique digestion patterns as assessed by agarose gel electrophoresis. Unique 
bands are diagnostic of no methylation (~4600 bp), methylation at site 1 (~5210 
bp), methylation at site 2 (~5830 bp), or methylation at both sites (~6580 bp). 
(D) A schematic of the functional methyltransferase at a target site. Zinc 
finger/DNA recognition mediates methyltransferase assembly. (E) This 
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assembly is designed not to occur at the non-target control site, which lacks 
zinc finger binding sites.  
2.3.4 Reduction of off-target activity through serial truncation of 
the C-terminal fragment 
We hypothesized that methylation at non-targeted sites resulted 
from the reassembly of the M.HhaI[1-209] and M.HhaI[210-326] 
fragments in the absence of the zinc finger binding sites, much like the 
M.HhaI[1-240] and M.HhaI[210-326] fragments that can assemble in an 
unassisted fashion [31]. We attempted to improve the bias for the target 
site through mutations designed to reduce the affinity of the two 
methyltransferase fragments for one another.   
The C-terminal α-helix of M.HhaI is located on the C-terminal 
fragment and interacts with a set of β-strands located on the N-terminal 
fragment. Together, the helix and β-strands comprise part of the 
Rossmann-like fold in M.HhaI [11]. We hypothesized that truncation of 
the C-terminal α-helix might disrupt this interaction by either reducing 
the overall stability of the C-terminal fragment or by simply reducing the 
surface area of the protein-protein interface. Thus, truncation of the C-
terminal helix was designed to prevent fragment reassembly when zinc 
fingers were not bound to their target sites, reducing off-target 
methylation. Zinc finger binding would facilitate the two fragments’ 
assembly at the target site.   
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Figure 2.4 The effect of C-terminal truncation, linker lengths, and target 




Figure 2.4 continued. The effect of C-terminal truncation, linker lengths, 
and target site spacing on methyltransferase activity (A) A schematic of the 
protein fusions and target DNA sequences indicating the variability in linker 
length and DNA spacing tested. The linkers connecting the zinc fingers to the N- 
and C-terminal fragments were varied in 5 amino acid increments (from 0 to 15 
amino acids), and combined iteratively. The bases separating the FspI site from 
the zinc finger binding sites were also varied (0,1,2,3 bases on each side). (B) 
Truncation of the C-terminus of the C-terminal fragment (indicated in units of 
amino acids) decreases off-target activity at the methyltransferase. In this 
experiment X=3, Y=1 and Z=0. The nature of the DNA at site 1 and site 2 
(whether a target or non-target site) is depicted at the bottom of the figure and 
graph. Constructs in which the C-terminus of M.HhaI was truncated by 6 
amino acids were used to determine the effect of (C) linker length and (D) target 
site spacing on methyltransferase activity at the target site. The percent 
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methylation at the target site are indicated in the graphs. All graphs show the 
mean and the error bar represents the standard deviation of the analysis of 
plasmid DNA from n ≥ 3 independent cultures.  
 
Figure 2.5 HhaI protection assay of C-terminal truncation variants shown 
in figure 2.4A (A) Analysis of plasmid DNA. HhaI endonuclease activity is 
blocked by methylation and one band is indicative of methylation and 
protection at the target site (site 1). Other, larger bands are indicative of off-
target methylation. There are 36 HhaI recognition sites on pDIMN8. Therefore, 
this assay cannot detect all of the off-target methylation as some bands 
indicative of off-target methylation may be obscured by other bands in the same 
lane and some may be too small to observe by this method. (B) Analysis of 
genomic DNA using FspI digestion. Chromosomal DNA was isolated from cells 
containing engineered M.HhaI constructs with a 6 or 4 amino acid C-terminal 
truncation where X = 3, Y = 1, Z = 0. The cells were grown under conditions 
known to repress or induce methyltransferase fragment expression (see 
Materials and Methods Fig. 2.4). The K12 chromosome has over 2000 FspI 
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restriction sites; thus, individual digestion products are not resolvable. For the 
6 amino acid-deletion variant this digestion pattern for chromosomal DNA 
isolated from cells with induced or repressed expression of the engineered 
methyltransferase is indistinguishable, indicating little to no methylation. 
However, for the 4 amino acid-deletion variant, induction of the engineered 
methyltransferase, shifts the digestion pattern toward higher molecular weight 
bands, which is indicative of some chromosomal methylation. As a control, 
chromosomal DNA treated with M.HhaI in vitro is protected from FspI digestion. 
The results show that our targeted methyltransferase (with the 6 amino acid 
truncation) causes little to no methylation of the chromosome. 
Based on the model of NZ/ZC, we used a long linker to connect the 
N-terminal fragment with HS1 and a short linker to connect HS2 with 
the C-terminal fragment (i.e. X=3 and Y=1 in Fig. 2.4A). No spacer 
nucleotides were placed between the FspI site and the HS1/HS2 binding 
sites (i.e. Z=0 in Fig. 2.4A).  
As shown in Figure 2.4B, the progressive deletion of 4 to 6 amino 
acids from the C-terminus of the C-terminal fragment resulted in the 
maintenance of a relatively high level of methylation at the target site 
(>50%) but a severe reduction in methylation at the non-target site.  
With 6 amino acids deleted, we observed 53±3% methylation of the target 
site and 1.4±2.4% methylation at the non-target site (Fig. 2.4B) 
Methylation was not apparent at any other M.HhaI site based on 
restriction digest protection assays with HhaI (Fig. 2.5A), though the 
assay is not as sensitive for methylation as the assay with FspI at the 
non-target site due to the large number of HhaI sites. Similarly, HhaI 
digestion of genomic DNA failed to provide any evidence of off-target 
methylation with our optimal construct (Fig. 2.5B), though significant 
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off-target methylation would need to occur for this assay to detect 
methylation on the chromosome. 
Bisulfite sequencing confirmed that methylation at the target site 
caused the observed protection from restriction enzyme digestion. 
Methylation predominantly occurred on one strand on the order of 50% 
(Fig. 2.6A).  No methylation could be detected at the non-target site by 




Figure 2.6 Bisulfite analysis of both strands. Continued on next page. 
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Figure 2.6 Bisulfite analysis of both strands at (A) the target site and (B) the 
non-target site. Bisulfite treatment followed by PCR amplification converts 
unmethylated cytosine bases to thymidine bases. Methylated cytosine residues 
are protected from such a conversion. The sense strand is defined as the top 
strand of the target and non-target sites shown in Figure 2.3D and E; the 
antisense strand is the bottom strand in these figures. Sequenced plasmid 
DNA, which was not bisulfite-treated is shown in column 1 row 1 of each panel. 
For both panels, the chromatogram of the antisense strand (column 2 row 1) is 
the computer-generated reverse complement of the chromatogram in column 1 
row 1. DNA in rows 2–6, was treated with the bisulfite reagent, amplified and 
sequenced as described in Methods S1. The plasmid tested was X = 15, Y = 5, Z 
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= 0 (see Figure 2.4). Rows 2 and 3 show sequencing results for bisulfite-treated 
unmethylated and methylated control DNA. Rows 4–6 show sequencing results 
for bisulfite-treated plasmid DNA from three independent cultures. The 
chromatograms for the following samples were converted to the reverse 
complement to simplify the comparison (target site, column 1, rows 4–6). 
2.3.5 The linker length’s effect on methylation at the target site is 
consistent with the model  
We next sought to investigate and optimize the length of the amino acid 
linkers connecting the M.HhaI fragments to their respective zinc fingers. 
Our previous work with targeted split methyltransferases indicated that 
linker length can affect enzymatic activity at the target site [110]. Using 
overlap extension PCR, we created N-terminal and C-terminal fragments 
that were fused to zinc fingers by linkers of 0, 5 10 and 15 amino acids 
(Fig. 2.4A). In all constructs, the C-terminal M.HhaI fragment had its last 
6 amino acids removed. All N-terminal fragment linker variants were 
then crossed with all C-terminal linker variants and tested for 
methylation activity at the target and non-target site (Fig. 2.4C). The 
target site lacked spacer nucleotides (Z=0). 
All constructs retained bias for methylation at the target site. We 
observed a reduction in methylation at the target site for shorter amino 
acid linkers connecting the N-terminal fragment with its respective zinc 
finger protein. Conversely, in the context of long N-terminal linker, an 
increase in the length of the linker connecting the C-terminal fragment 
and its respective zinc finger resulted in a decrease in methylation at the 
target site. 
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The relationship between linker length and activity at the target 
site can be explained by our model of the NZ/ZC/DNA complex. As 
shown in Figure 2.1C, the optimal 15 amino acid linker, connecting the 
HS1 zinc finger to the N-terminal fragment, is found to wrap around the 
DNA backbone. A longer linker is required because the N-termini of the 
zinc finger and the bisection point of the N-terminal methyltransferase 
fragment are located on opposite sides of the DNA. Shortening the linker 
reduces the probability of interaction between the N-terminal M.HhaI 
fragment with the C-terminal M.HhaI fragment upon HS1 zinc finger 
binding, thereby reducing methylation at the target site. On the other 
hand, the close proximity of the N-terminus of the C-terminal M.HhaI 
fragment and HS2 zinc finger indicates that a short linker would be 
sufficient between these two domains. However, it would be less 
entropically favorable for a longer flexible linker between these domains 
to assist in the assembly of an active enzyme. An overly long linker 
enables the C-terminal fragment to explore more space upon zinc finger 
binding, compromising the increase in local concentration of the C-
terminal fragment gained by zinc finger binding. 
2.3.6 The orientation of the zinc finger binding sites relative to the 
methylation site modulates targeted methylation 
We next sought to characterize the effect of adding bases between the 
zinc finger binding sites and the FspI site (i.e. varying Z in Figure 2.4A). 
The addition of bases both increases the distance in the DNA sequence 
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and rotates the zinc finger binding sequence around the DNA with 
respect to the central CpG site. Due to this rotation, the addition of bases 
can potentially increase or decrease the required length of the linker 
joining the methyltransferase fragment and the zinc finger.   
To test this idea, we used three sets of linker variants in which the 
sum of the number of linker residues was kept constant (X=1/Y=3, 
X=2/Y=2, and X=3/Y=1). A constant sum total of linker residues helps 
illustrate that total linker length does not determine enzymatic activity at 
the target site. For each set of linker variants, we added 0, 1, 2 or 3 bp to 
both sides of the FspI site and tested methyltransferase activity as 
before. All constructs retained some methylation at the target site and 
minimal methylation at the non-target site; however, the length of the 
spacer DNA modulated activity in a complex manner (Fig. 2.4D).  
 
Figure 2.7 Molecular modeling explains how an increase in target spacing 
can reduced the required protein linker length (A) HS1 zinc fingers are 
bound to DNA with a target site spacing of Z=0,1,2, or 3. Note that at Z=3, the 
zinc finger is actually closer to the bisection point of the N-termini than at Z=0.  
(B) A model demonstrating that a five amino acid linker is sufficient to connect 
zinc finger HS1 bound at Z=3. In contrast, a longer amino acid linker is 
required to circumvent the DNA backbone at Z=0. This model provides an 
explanation for the pattern of target site methylation observed in Figure 3D. 
Krishna Praneeth Kilambi created the pymol models used to make this image. 
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The NZ/ZC/DNA model provides a rationale for the observed 
behavior. For X=1/Y=3/Z=0, methylation at the target site remains low 
because the linker between the N-terminal M.HhaI fragment and its 
respective zinc finger is too short. However, methylation at the target site 
increases to 58% at the highest spacer length (Z=3) because the linker 
between these domains no longer needs to wrap around the DNA 
backbone (Fig. 2.7A). When Z=3, modeling indicates that a five amino 
acid linker (X=1) between the two domains is sufficient for fragment 
reassembly at the target site (Fig. 2.7B). 
For linker combinations that possess high target site methylation 
with Z=0 (i.e. X=2/Y=2 and X=3/Y=1), the addition of 1 or 2 bp reduces 
methylation at the target site. However, the addition of 3 bases restores 
target site methylation to their Z=0 levels (Fig. 2.4D). The initial 
reduction of activity with the addition of 1 or 2 bp can be explained by 
the rotation of the zinc fingers further around the DNA such that the 
linkers have to span even longer distances for reassembly to occur. 
However, modeling predicts that with the addition of 3 bp, the linker no 
longer needs to wrap around DNA and the distance can now be spanned 
by a 5 amino acid linker connecting the N-terminal fragment and HS1 
(Fig. 2.7B). 
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2.3.7 Zinc finger mediated localization of both M.HhaI fragments 
has a synergistic effect on methylation targeting 
We desire targeted methyltransferases that require the binding of both 
zinc finger domains for methyltransferase activity.  
 
Figure 2.8 The contribution of each zinc finger binding site toward 
observed, targeted DNA methylation Methylation was assessed as in Figure 
2. In this experiment, the C-terminal fragment of M.HhaI is truncated by 6 
amino acids, X=3, Y=1, and Z=0. Methyltransferase activity was assessed with 
and without target sites present. Moving the target site from site 1 to site 2 did 
not have a large effect on activity. Target half sites (in which either the HS1 or 
HS2 binding sites were removed) allowed assessment of the contribution of each 
zinc finger on methylation activity at the target site. The sum of the methylation 
observed on each half site (43±5%) was less than methylation at the full target 
site (61±6%). The methylation observed with two distal half sites (<30%) was 
also less than that observed with the complete target site. 
However, all linker length and spacer DNA variants tested (Fig. 2.4 C and 
D) retained some bias for methylating the target site, despite our models’ 
prediction that some variants have insufficient length linkers to allow 
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target site reassembly. This suggests that some of the methylation 
observed at the target site may occur without binding of both zinc 
fingers. In other words, the bias for methylation at the target site may 
occur in part through localization of only one of the two fragments via its 
zinc finger domain, followed by a reassembly of M.HhaI that is 
independent of a second zinc finger-binding event. 
To test this hypothesis, target “half sites” were constructed with 
either the HS1 or the HS2 zinc finger binding site (Fig. 2.8). These 
experiments were conducted with a construct containing a high degree of 
specificity and activity for the full HS1/HS2 site (i.e. X=3, Y=1, Z=0). The 
amount of methylation at the target and non-target sites was assessed as 
before. Removal of either (but not both) of the zinc finger binding sites 
reduced, but did not eliminate methylation at the target site (Fig. 2.8). 
Removal of the HS1 binding site was more detrimental to methylation 
activity at the target site than removing the HS2 site, indicating that 
localizing only the N-terminal M.HhaI fragment via zinc fingers was more 
effective for targeting methylation than localizing only the C-terminal 
fragment via zinc fingers. This result may be explained by the fact that 
the target recognition domain (TRD) is present on the C-terminal 
fragment. Thus, the C-terminal fragment likely possesses greater 
inherent affinity for the methylation target site than the N-terminal 
fragment. In other words, the N-terminal fragment has a greater need for 
fusion to the zinc finger in order to localize it to the target site. This 
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result is unlikely to be explained by differences in the DNA binding 
affinity of the two zinc finger proteins. HS1 and HS2 have similar 
dissociation constants for their target sites (35 nM and 25 nM, 
respectively) [163]. 
Although this experiment revealed a shortcoming of our current 
optimized, split M.HhaI, it also provides evidence for the advantages of 
targeting methyltransferases using our split enzyme strategy. The level of 
target site methylation observed at a CpG site flanked by both zinc finger 
binding sites (61±6%) exceeds the sum of the methylation observed at the 
half sites (43±5%)(Fig. 2.8). This synergy (i.e. the observed activity at the 
intact target site is greater than the sum of activity observed at the 
individual binding sites), is caused by the proximity of zinc finger binding 
sites and is precisely what our split enzyme system was designed to 
achieve. We also confirmed that placing the two zinc finger sites at 
distant locations on the same plasmid cannot provide the same level of 
targeted methylation observed by placing both zinc finger sites at one 
target site (Fig. 2.8).  
2.3.8 M.SssI can be converted into a heterodimeric/zinc finger 
fusion enzyme, whose activity is biased towards a desired 
target site  
We were interested in assessing whether other monomeric 
methyltransferases could be bisected and fused to zinc finger proteins to 
create targeted methyltransferase. Specifically, we were interested in 
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bisecting M.SssI, a prokaryotic methyltransferase that recognizes and 
methylates the cytosine of any 5’-CG-3’ site. A targeted methyltransferase 
derived from M.SssI would, in theory, make it possible to target any CpG 
site, rather than just 1/16 of the possible CpG sites that could be 
methylated by our engineered M.HhaI enzyme (which recognizes 5’-
GCGC-3’).  
We used a CLUSTALW alignment to identify a site within M.SssI that was 
similar to the split site of M.HhaI [165,166]. We fused the zinc finger 
proteins HS1 and HS2 in the same NZ/ZC orientation as our targeted 
M.HhaI fusion proteins using 15 and 10 amino acid linkers, respectively 
(Fig. 2.9A). These constructs were tested for methylation specificity in an 
analogous fashion to that illustrated in Figure 2.3. Methylation activity 
was assessed under conditions shown to either induce or repress 
expression of the methyltransferase fragments. Upon induction, the 
fusion constructs were very active and, although some bias towards the 
target site was apparent, the high activity prevented the observation of 
the extent of this bias (Fig. 2.9B). Slaska-Kiss et al very recently 
demonstrated that M.SssI is amenable to protein fragment 
complementation at select sites; however, targeted methylation was not 
demonstrated [112].   
We used site-specific mutagenesis to reduce methyltransferase 
activity in order to reveal the inherent bias of the construct (Fig. 2.9B). 
Mutating the active site cysteine, C141S, has been shown to reduce the 
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activity of M.SssI enough to reveal biased methylation activity upon 
M.SssI fusion to triple helix forming nucleotides [104]; however, in the 
context of our bisected enzyme, this mutation completely eliminated 
activity in vivo (Fig. 
2.9B).
 
Figure 2.9 M.SssI can be converted into a targeted heterodimeric 
methyltransferase (A) A schematic showing the sequence of the M.SssI 
fragments fused to zinc fingers via flexible linkers. (B) A restriction enzyme 
protection assay showing the split enzyme constructs possess a bias for 
methylation at the target site. Plasmids were isolated from strains grown under 
conditions that either repress or induce expression of the two fragments. 
Plasmid DNA was assayed for methylation as in Figure 2. The activity of these 
fusion heterodimers was attenuated by the indicated point mutations known to 
decrease enzyme activity in wild-type M.SssI. 
 On the other hand, both the Q147L and S317A mutations, which 
are known to reduce M.SssI’s DNA binding affinity by 12-fold and 3-fold 
respectively [26], reduced but did not eliminate the activity of our 
bisected M.SssI, revealing the extent of our enzyme’s methylation bias 
(Fig. 2.9B). The relative activity of the two mutants was consistent with 
the reported relative effect of the mutations on M.SssI affinity for DNA. 
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2.4 Conclusions 
We have demonstrated that bisected M.HhaI and M.SssI enzymes, when 
fused to zinc fingers in the proper orientation, can target methylation to 
a desired sequence flanked by the respective zinc finger binding sites. 
Our modeling and experiments have elucidated some of the design 
principles for constructing a targeted methyltransferase using this 
strategy. The orientation of methyltransferase fragments relative to each 
other and to DNA affect the activity at the target site. Mutations designed 
to reduce the interaction between fragments can improve targeting of the 
methyltransferase. With the proper linker length, spacing between zinc 
finger binding and methylation sites, and expression conditions, such 
constructs can methylate a desired target with high efficiency (50-60%) 
with levels of non-target site methylation at or below the limit of 
detection. Part of the targeting arises from the synergistic effect of 
localizing both fragments to the desired site, which supports our 
hypothesis of how bisected enzymes could better target methylation.  
However, some of the bias for methylation at the target site likely 
arises from zinc finger mediated localization of only one of the two 
fragments. Thus, although binding of both zinc finger domains increases 
target site methylation, such methylation does not yet require binding of 
both zinc finger domains. We believe this limitation arises because the 
individual N- and C-terminal fragments (particularly the C-terminal 
fragment) retain some affinity for the 5’-GCGC-3’ site and, perhaps, 
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retain sufficient affinity for each other. We next intend to test these 
hypotheses experimentally in a manner that is guided by our 
computational model.  
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3 Directed evolution of improved zinc finger 
methyltransferases 
3.1 Introduction  
CpG methylation is one of the most extensively studied epigenetic 
modifications and broadly regulates or maintains transcriptional activity. 
As discussed in the introductory chapter, methylation of DNA is involved 
in proper cellular differentiation, heterochromatin formation and 
chromosomal stability [68]. Further, aberrant methylation patterns cause 
or are observed in numerous diseases. Imprinting defects lead to 
disorders such as Prader-Willi and Angelman syndromes [167]. Notably, 
aberrant methylation of CpG islands (CGIs) is a hallmark of cancer [69]. 
Though much has been learned about how methylation patterns are 
established and erased, the causes of aberrant methylation and the 
reestablishment of methylation patterns during development remain 
active areas of research. To study the effects and dynamics of DNA 
methylation, it would be generally useful to target methylation toward 
specific, user-defined sequences. 
In the previous chapter, we described how a split version of M.SssI 
DNA methyltransferase fused to zinc finger proteins demonstrates bias 
for methylating a M.SssI site located between the two zinc finger binding 
sites [168]. The bifurcation point in M.SssI was chosen based on a 
CLUSTALW alignment to a site in a similarly engineered M.HhaI enzyme 
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[168]. However, site specific mutations Q147L or S317A in the M.SssI 
domain, introduced to reduce the enzyme’s DNA binding affinity and 
activity, were necessary to observe significant bias towards methylation 
at a target site [168]. Here we present a selection strategy to improve the 
targeting of methyltransferases and have used this strategy to optimize 
our M.SssI fusion construct. We performed a negative selection against 
off-target methylation and a positive selection for methylation at a target 
site, in vitro. This strategy allowed us to quickly identify variants with 
improved targeting ability and activity in vivo. We also demonstrate the 
modularity of our constructs by altering the zinc finger domains to 
redirect methylation toward a new target site.  
3.2 Materials and methods 
3.2.1 Enzymes, oligonucleotides and bacterial strains 
Restriction enzymes, T4 ligase, T4 kinase, and Phusion High Fidelity PCR 
MMX were purchased from New England Biolabs (Ipswich, MA). BoxI was 
purchased from ThermoFisher Scientific (Waltham, MA). Platinum Pfx 
DNA polymerase was purchased from Life Technologies (Carlsbad, CA). 
PfuTurbo Cx Hotstart DNA polymerase was purchase from Agilent 
Technologies (Santa Clara, CA). Plasmid-Safe-ATP-dependent DNAse was 
purchased from Epicentre (Madison, WI). pDIM-N8 and pAR plasmids 
have been previously described [110,168]. All oligonucleotides and 
gBlocks were synthesized by Invitrogen (Carlsbad, CA) or Integrated DNA 
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Technologies (Coralville, IA). Gel electrophoresis and PCR were preformed 
essentially as previously described [162]. Plasmids were isolated using 
QIAprep Spin Miniprep Kit (Qiagen, Valencia, CA). DNA fragments were 
purified from agarose gels using QIAquick Gel Extraction Kit (Qiagen, 
Valencia, CA) or PureLink Quick Gel Extraction Kit (Invitrogen, 
Carlsbad,CA, USA) and further concentrated using DNA Clean & 
Concentrator-5 (Zymo Research, Irvine, CA). 
Escherichia coli K-12 strain ER2267 [F´ proA+B+ lacIq Δ(lacZ)M15 
zzf::mini-Tn10 (KanR)/ Δ(argF-lacZ)U169glnV44 e14-(McrA-) rfbD1? recA1 
relA1? endA1 spoT1? thi-1 Δ(mcrC-mrr)114::IS10] was acquired from New 
England Biolabs (Ipswich, MA) and was used in selections, methylation 
assays and cloning.  
3.2.2 Plasmid creation 
pDIMN8, was used for library creation and testing of library variants 
[168]. pDIMN9 was constructed as follows for use in golden gate cloning. 
Plasmid pDIMN8 was altered by silently mutating a BsaI site in the AmpR 
gene via pFunkel mutagenesis [169]. PCR, digestion and cloning removed 
a BbsI restriction site to create vector pDIMN9. Golden gate cloning was 
used to fuse new zinc finger proteins to methyltransferase fragments. For 
the creation of plasmids used in golden gate cloning, regions encoding 
zinc finger proteins were replaced with BbsI sites. pDIM-N9 contained a 
M.SssI[1-272]-BbsI construct for the addition of zinc fingers to the N-
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terminal fragment. pAR contained BbsI-M.SssI[273-386] construct for 
the addition of new zinc fingers to the C-terminal fragments [110]. 
gBlocks encoding zinc fingers and BbsI sites were purchased from IDT. 
Golden gate cloning to fuse zinc finger encoding gBlocks to the above 
plasmids was performed essentially as described [170]. Zinc finger 
CD54a was designed using the zinc finger tools website and previously 
identified zinc finger domains [139,143,145]. Individual C-terminal and 
N-terminal zinc finger-fused constructs were digested with EcoRI and 
SpeI as previously described to place these constructs on the same 
plasmid for characterization in E. coli [110]. Site 1 and site 2 were altered 
as previously described to vary the sequences flanking different CpG 
sites [168]. 
3.2.3 Construction of cassette mutagenesis library 
An NNK codon mutagenesis library of M.SssI[273-386] was constructed 
by overlap extension PCR. PCR was carried out using an oligonucleotide 
degenerate for a five amino acid region in the C-terminal fragment 
corresponding to amino acids 297-301 in the wild type enzyme. 
Fragments were digested with AgeI-HF and SpeI and ligated into pDIMN8 
containing HS2 and the complete N-terminal fragment-HS1 fusion. Site 1 
(i.e. the target site in Fig. 3.1C) contained an FspI site flanked by HS1 
and HS2 zinc finger recognition sites. The plasmid also possessed a non-
target site that lacked zinc finger binding sites, but contained an internal 
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SnaBI restriction site (red site in Fig. 3.2A). Ligations were transformed 
into ER2267 electrocompetent cells and plated onto agarose plates 
containing 100 μg/ml ampicillin and 2% w/v glucose. Plates were 
incubated overnight at 37°C. The naive library contained 2 x 105 
transformants. 
3.2.4 Library selection  
Plated library variants were recovered from the plate in lysogeny broth 
supplemented with 15% v/v glycerol and 2% w/v glucose and stored at -
80°C. Aliquots were thawed and used to inoculate 10 ml of lysogeny 
broth supplemented with 100 μg/ml ampicillin salt, 0.2% w/v glucose, 1 
mM IPTG, and 0.0167% w/v arabinose. These cultures were incubated 
overnight at 37°C and 250 rpm. Plasmid DNA was isolated via QIAprep 
Spin Miniprep Kit and digested for 3 hours at 37°C with McrBC (10 
units/μg DNA), FspI (2.5-5 units/μg DNA) in 1X NEBuffer 2 
supplemented with 100 μg/ml BSA and 1mM GTP. Reactions were halted 
by incubation at 65°C for over 20 min minutes to which ExoIII (30 
units/μg DNA) was added and the solution incubated at 37°C for 60 min. 
ExoIII digestion was halted by incubation at 80°C for over 30 minutes 
and the DNA was desalted using Zymo Clean and Concentrator-5 kits per 
manufacturer’s instructions. DNA was transformed into ER2267 
electrocompetent cells and plated on agar supplemented with 2% w/v 
glucose and 100 μg/ml ampicillin salt.   
 75 
Cells were recovered from the plate as before and plasmid DNA was 
isolated using the QIAprep Spin Miniprep Kit. The DNA was digested with 
FspI (2-2.8 units/μg DNA) in 1X NEBuffer 4 and linear DNA was isolated 
via gel electrophoresis. PCR was used to amplify the portion of the linear 
plasmid containing genes encoding for the N-terminal and C-terminal 
fragments fused to zinc fingers. Purified PCR products were subcloned 
into the selection plasmid for an additional round of selection. 
3.2.5 Restriction endonuclease protection assays 
Cultures from colonies were incubated overnight at 37°C and 250 rpm 
and stored as glycerol stocks. Glycerol stocks were used to inoculate 10 
ml of lysogeny broth supplemented with 100 μg/ml ampicillin salt, 0.2% 
w/v glucose, 1 mM IPTG, and 0.0167% w/v arabinose. After growth 
overnight at 37°C, plasmid DNA was purified from the cultures by 
QIAprep Spin Miniprep Kit. Plasmid DNA (500 ng) was digested with 
NcoI-HF (10 units) and either FspI (2.5 units) or SnaBI (2.5 units) in 1X 
NEBuffer 4 for over one hour at 37°C. SnaBI digests were supplemented 
with 100 μg/ml BSA. Half of each digested sample was loaded onto 
agarose gels (1.2% w/v in TAE) and electrophoresed at 90 V for 105-120 
minutes. Bands were quantified as described [168]. 
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3.3 Results and discussion  
3.3.1 Design of the selection system 
M.SssI naturally methylates CpG sites [23]. Our previously described, 
bifurcated M.SssI DNA methyltransferase zinc finger fusions (Fig. 3.1B) 
biased methylation toward a targeted M.SssI site flanked by the cognate 
zinc finger binding sequences. However, active variants also methylated 
other M.SssI sites [168]. We sought to reduce this off-target methylation 
while maintaining high levels of methylation at the targeted M.SssI site. 
Here, we describe an in vitro selection system that preferentially enriches 
variants possessing the ability to methylate the target site, but lacking 
the ability to methylate other non-targeted M.SssI sites on the plasmid 
(Fig. 3.1D). 
In vitro selection strategies have been used to enrich for 
methyltransferases with relaxed or altered specificity. Most strategies rely 
on methylation-dependent protection from restriction endonuclease 
digestion to positively select for DNA encoding a methyltransferase with 
altered specificity [95-98]. Our selection scheme differs from previous 
studies as it additionally employs McrBC as a negative selection against 
unwanted methylation activity. In our system for altering 
methyltransferase specificity, a single plasmid contains both genes 
encoding the zinc finger-fused M.SssI fragments as well as a targeted 
M.SssI site nested within an FspI restriction site and flanked by zinc 
finger binding sites (Fig. 3.1A and C).  
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Figure 3.1 Schematics of the vector, library, proteins, and selection used 
in these experiments (A) The vector used in selections. The vector encodes for 
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both heterodimeric fragments fused to zinc fingers under the control of separate 
inducible arabinose (pBAD) and IPTG (lac) promoters, a target site, and the 
araC gene. (B) A scheme of the zinc finger-fused, bifurcated M.SssI and the 
mutagenized codons used in library construction. Residues 297-301 of M.SssI 
(located in the C-terminal fragment) were randomized. Numbering scheme is 
that of the wildtype M.SssI. (C) An assembled zinc finger-fused heterodimeric 
M.SssI methyltransferase assembled at the target site. (D) An overview of the 
selections used in this experiment. The schematic illustrates the fates of 
plasmids encoding an inactive methyltransferase (left), the desired targeting 
methyltransferase methylating the target site (middle) and a nonspecific 
methyltransferase methylating multiple M.SssI (i.e. CpG) sites. 
The plasmid also has over 400 other M.SssI (i.e. CpG) sites. Once 
transformed into E. coli, the methyltransferase fragments encoded by the 
plasmid are expressed, resulting in methylation of the same plasmid. The 
plasmid DNA is isolated and subjected to in vitro digestions with 
endonucleases FspI and McrBC (Fig. 3.1D). Since FspI digestion is 
blocked by methylation at the target site, FspI digestion serves to select 
for methylation at the targeted CpG site. McrBC is an endonuclease that 
recognizes and cleaves DNA with two distal methylated sites [171,172]. 
McrBC will not digest a single site that is methylated or hemimethylated 
unless there is a second methylated site on the same DNA within about 
40-3000 bp [173]. We therefore expect that most plasmids methylated at 
multiple M.SssI sites will be digested by McrBC. Thus, McrBC digestion 
selects against off-target methylation. The DNA is then incubated with 
ExoIII to degrade any plasmid that is digested at least once, ideally 
leaving the plasmid DNA encoding a highly specific methyltransferase 
intact for the subsequent transformation. 
Initial proof of principal selections demonstrated that McrBC, FspI 
and ExoIII treatment of unmethylated plasmid DNA, followed by 
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transformation resulted in a 99.85% decrease in the number of 
transformants relative to untreated DNA. Similarly, McrBC, FspI and 
ExoIII treatment of a highly methylated plasmid reduced transformants 
by 99.95% relative to untreated control.  
3.3.2 Design of the library 
We constructed a library of M.SssI C-terminal fragment variants 
randomized at residues 297-301 (Fig. 3.1B). We hypothesized that 
mutations to these residues might reduce the ability of the split 
methyltransferase to methylate non-targeted CpG sites by reducing the 
fragment’s inherent affinity for double-stranded DNA. Early studies 
indicated that M.SssI interacts with DNA, irrespective of the presence of 
CpG sites and subsequently methylates processively [174]. Further, a 
homology model of M.SssI suggested that residues 297 and 299 form 
contacts with the ribose phosphate backbone on the CpG bases 
complementary to the methylated CpG site [24]. Mutational studies 
showed that for monomeric M.SssI, K297A or N299A mutations did not 
appreciably affect either the catalytic activity or the dissociation constant 
of a CpG containing oligonucleotide [26]. Mutating these residues, we 
hypothesized, might eliminate the innate affinity of our fragments for 
DNA without affecting the catalytic activity of the enzyme. 
Additionally, the homology model indicated the amide backbone of 
serine residue at position 300 made base-specific contacts with the 
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cytosine and guanine bases complementary to the methylated strand. 
This model initially implicated serine’s conserved and catalytically 
important role for stabilizing the complementary strand during base 
flipping and methylation [24]. However, the S300P mutation resulted in 
only a three-fold increase in a dissociation constant and no significant 
change in initial rate of reaction [25].  
3.3.3 Library selections 
Initial selection experiments on this library resulted primarily in the 
isolation of plasmid DNA with a deleted FspI restriction site, presumably 
formed by a recombination event. This false positive was a trivial, albeit 
frequently observed solution for plasmid survival in our devised scheme. 
Thus, we subjected the plasmid DNA from the resulting transformants to 
additional steps to enrich for those plasmids that survived our selection 
and retained their FspI site. In these additional steps, the plasmid DNA 
was transformed into ER2267 cells and the cells were plated under 
conditions known to repress the promoters controlling methyltransferase 
fragment expression. We digested plasmid DNA from these cells with FspI 
and purified the linear, FspI-digested DNA away from undigested plasmid 
DNA by agarose gel electrophoresis. The portion of the plasmid encoding 
the zinc fingers and methyltransferase genes was PCR amplified, ligated 
back into the same plasmid backbone. This entire procedure was 
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repeated, subjecting variants to an additional round of selection. Selected 
variants were then analyzed. 
3.3.4 Analysis of library variants that survived the selection 
We assayed 47 variants for methylation activity at both the target and 
non-target site and determined the variants’ sequences. The best 
variants (e.g. PFCSY, CFESY, and SYSSS, which are named for the 
sequence at residues 297-301) methylated 65-80% of the plasmids at the 
target site with minimal methylation (0-8%) at the non-target site (Fig. 
3.2). 
 
Figure 3.2 Methylation assay for selected variants (A) Relative locations of 
the target site and non-target site on a plasmid linearized by NcoI digestion. (B) 
The target site is comprised of the HS1 and HS2 zinc finger recognition sites 
flanking an internal FspI restriction site. The targeted CpG site is nested within 
this FspI restriction site (C) The non-target site lacks the HS1 and HS2 
recognition sequences, but contains a SnaBI restriction site with a nested CpG 
site for the assessment of off-target methylation (D) The restriction 
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endonuclease protection assay for methylation at the target and non-target site 
uses digestion with NcoI and either FspI or SnaBI for assessment of target and 
non-target methylation, respectively. FspI and SnaBI cannot digest a 
methylated site. Shown are results from select variants as well as the ‘wildtype’ 
heterodimeric enzyme (i.e. no mutations to residues 297-301) with or without a 
catalytically inactivating (C141S), or a catalytically compromised (Q147L) 
mutation.  
Most variants displayed biased methyltransferase activity toward 
the targeted site. A complete list of sequenced variants can be found in 
Table 1. A comparison of the sequences of active variants, using weblogo 
3.3, indicated that a functional heterodimeric methyltransferase strongly 
preferred certain residues at positions 298 and 300 (Fig. 3.3) [175,176]. 
Position 298 (wildtype phenylalanine) was almost exclusively composed 
of aromatic residues. Position 300 (wildtype serine) was almost 
exclusively composed of small residues (defined as an amino acid with an 
R side chain containing 1-3 heavy atoms). The observed conservation at 
these residues is consistent with sequence alignments showing these two 
residues are relatively well-conserved among methyltransferases of 
different species [24].  
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 In contrast, positions 297, 299 and 301 exhibited little preference 
for specific amino acids. This finding is consistent with the mutational 
studies discussed above, as these residues were not found to be 
important for the catalytic activity of the monomeric enzyme[26]. Our 
study reveals that there are numerous solutions for improving the 
specificity of our zinc finger-fused, bifurcated methyltransferases.  
To further characterize some of these variants, we cloned library 
fragments into plasmids containing either a control non-target site 
(lacking both zinc finger binding sites) or a half-site (lacking one of the 
zinc finger sites) adjacent to the FspI restriction site.  
As with our previously described split M.HhaI constructs, these 
split M.SssI constructs did not require the presence of both zinc finger 
binding sites for methylation activity (data not shown) [168]. However, 
CFESY and SYSSS exhibited a synergistic activity caused when both zinc 
finger recognition sites flanked the targeted CpG site. In other words, the 
observed activity at the full site was greater than the additive effects of 





Figure 3.3 Sequence conservation at residues 297-301 of all catalytically 
active selected variants (A) The wild type sequence for residues 297-301 (B) A 





Amino acid at position 
assayed active notes K297 F298 N299 S300 E301 
1 T F T A H x x  
5 P Y C S F x x  
6 G W H S Y x x  
7 C F E S Y x x  
8 V F M * L    
9 R F D S L x x  
12 S F R C D x x  
13 Y L N G I x   
14 S W L S S x x  
15 C F A S S x x  
16 R R I L *    
18 L F L S A x x  
21 R W A S *    
22 S Y S S S x x  
23 K F N S E x  WT 
24 L W N A S x x  
25 H F T S S x x  
26 G F E S F x x  
29 S F T A R x x  
30 S F V S T x x  
31 K F N S E   WT 
32 S Y H S V x x  
34 G Y K C R x x  
35 P F F C H x x  
37 L K C G G x   
41 C F A S S  x duplicate 
42 L Y Y C E x x  
43 L W A S L x x  
45 S Y S C Y x x  
46 R Y V S L x x  
47 S Y A * M    
49 L Y R * E    
50 A W D C S x x  
54 P F C S Y x x  
56 Y F L S E x x  
58 L F T A Y    
59 N Y R A L x x  
62 P Y C S F  x duplicate 
63 S F R C D  x duplicate 
64 N F R A D x x  
66 F W W V G x   
67 P Y T S N x   
69 S Y S S Y x x  
70 L * * Y P    
71 T F T A H  x duplicate 
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75 S Y H S V  x duplicate 
76 P F V S H x x  






88 N F P S F x x  
92 A W T S V x x  
95 S Y D S L x x  
98 T F N C E x x  
99 S Y H S V  x duplicate 
100 F W S S Q x x  
101 P F C S Y  x 
duplicate on 




102 A F D S S x x  
103 I Y L Q E x x  
105 S Y V S L x x  
107 G T P C T x x  
109 V F G C P x x  
110 P F T S Y x x  
114 T W F S S x x  
116 H F T S S  x duplicate 
Table 1: Complete list of variants sequenced, assayed and confirmed to 
have methyltransferase activity Yellow indicates aromatic residues. Blue 
indicates “small” residues as defined in the text. 
3.3.5 The targeted heterodimeric methyltransferases are modular 
To test whether or not our targeted M.SssI methyltransferases are 
modular with respect to the zinc finger domains, we replaced zinc fingers 
HS1 and HS2 with two zinc fingers designed to target a specific site in 
the promoter of intercellular adhesion molecule 1 (ICAM1). The 
previously designed zinc finger CD54-31Opt [177] is adjacent to a CpG 
site in this promoter. To generate a pair of zinc fingers capable of 
flanking this CpG site, we designed a second zinc finger, CD54a, to bind 
downstream from the recognition sequence of CD54-31Opt and adjacent 
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to the targeted CpG site. The two zinc fingers were fused to fragments 
comprising non-optimized bifurcated M.SssI fragments (residues KFNSE 
at positions 297-301) and to two selected variants (CFESY and SYSSS at 
positions 297-301), replacing the HS1 and HS2 zinc fingers (Fig. 3.4A). 
These two optimized variants were chosen because methylation at the 
target site (containing both zinc finger binding sites) was greater than the 
additive amount of methylation levels observed at half sites, as discussed 
above.  
We assessed the methyltransferase activity and specificity of these 
constructs in E. coli with a restriction endonuclease protection assay 
(Fig. 3.4C and D). Although all three constructs biased methylation to 
the target site from the ICAM1 promoter, only the CFESY and SYSSS 
constructs targeted methylation to the desired site with little to no 
observable methylation at the non-target site (Fig. 3.4D). Notably, the 
‘non-target’ site in this experiment contained the zinc finger sites 
recognized by HS1 and HS2 (Fig. 3.4B). 
The CD54-31Opt was chosen because it was shown to effectively 
target the ICAM1 promoter, altering transcription levels when bound to 
transcriptional activators or repressors [83,177]. Additionally, fusion of 
CD54-31Opt to Ten-Eleven Translocation gene 2 resulted in a small, 
observable amount of demethylation around the target site, correlating 
with a 2-fold upregulation in ICAM1 transcription [84]. Our construct 
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may potentially enable assessment of the biological effects of targeted 
methylation at this site. 
  
 
Figure 3.4 Substitution of new zinc fingers targets methylation towards a 
new site (A) A schematic of the designed methyltransferase is shown assembled 
over the new targeted CpG site. New cognate zinc finger recognition sequences 
flank a CpG site nested within an FspI site. Zinc fingers CD54-31Opt and 
CD54a have replaced the HS1 and HS2 zinc fingers. (B) The non-target site 
contains the HS1 and HS2 zinc finger recognition sites flanking a CpG site 
nested within a FspI restriction site (i.e. this was the target site used in the 
experiments shown in Figure 2). (C) The relative locations of the target site and 
non-target sites are shown on a plasmid linearized by NcoI digestion. (D) The 
restriction endonuclease protection assay for methylation at the target and non-
target site for the ‘wildtype’ heterodimeric enzyme (KFNSE) and two selected 
variants with mutations in the region 297-301. 
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4 Initial tests in eukaryotic cells 
4.1 Introduction 
Our targeted methyltransferases may be useful as tools to study the 
phenotypic effects of site-specific methylation at different promoters. 
These enzymes would also enable us to observe how epigenetic 
alterations spread or are corrected in human cell lines. Finally, if a 
hypomethylated region of DNA is responsible for a disease state, a 
targeted construct might act as a potential therapeutic. However, before 
a targeted methyltransferase can be utilized in these contexts, it will be 
necessary to show that zinc finger-fused heterodimeric 
methyltransferases are functional in eukaryotic cells. In E. coli, we have 
shown that expression levels of zinc finger-fused methyltransferase 
fragments affect the activity and function of these enzymes [110]. Thus, 
in eukaryotic cells, the stability, expression levels, toxicity, and nuclear 
transport may also affect the function of these enzymes. In addition, DNA 
within the chromosome may be less accessible than plasmid DNA. As 
discussed in Chapter 1, other biased methyltransferases have 
successfully methylated eukaryotic chromosomal DNA. However, it is 
unknown whether our heterodimeric methyltransferases will be able to 
methylate the chromosome as well. 
The goals of this research were to demonstrate that 1) 
methyltransferase fragments could be expressed in human cell lines, 2) 
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methylation could be targeted to a specific site in a mammalian 
expression vector and 3) heterodimeric methyltransferases could 
methylate chromosomal DNA in human cell lines. Achieving these goals 
would provide the proofs of principle necessary for larger-scale studies 
attempting to target the methyltransferase to specific CpG sites within 
eukaryotic chromosomal DNA.  
4.2 Materials and methods 
4.2.1 Reagents and bacterial strains 
Restriction endonucleases, T4 ligase, T4 PNK, and Phusion High Fidelity 
MMX were purchased from New England Biolabs (Ipswich, MA). 
Oligonucleotides and gBlocks were purchased from Integrated DNA 
Technologies (Coralville, IA). For cloning and sequencing, plasmids were 
isolated using QIAprep Spin Miniprep Kit (Qiagen,Valencia, CA). DNA 
fragments and PCR products were purified from agarose gels using 
PureLink Quick Gel Extraction Kit (Life Technologies, Carlsbad,CA, USA) 
and further concentrated using DNA Clean and Concentrator-5 (Zymo 
Research, Irvine, CA) according to manufacturers instructions. 
Escherichia coli K-12 strain ER2267 [F proA+B+ lacIq D(lacZ)M15 
zzf::mini-Tn10 (KanR)/D(argF-lacZ)U169 glnV44 e14–(McrA–) rfbD1? recA1 
relA1? endA1 spoT1? thi-1 D(mcrC-mrr)114::IS10] was acquired from New 
England Biolabs (Ipswich, MA) and was used for cloning. NEB 10-beta 
Competent E. coli (High Efficiency) [Δ(ara-leu) 7697 araD139  fhuA 
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ΔlacX74 galK16 galE15 e14- φ80dlacZΔM15  recA1 relA1 endA1 nupG  
rpsL (StrR) rph spoT1 Δ(mrr-hsdRMS-mcrBC)] and NEB 5-alpha  
Competent E. coli (High Efficiency) [fhuA2D(argF-lacZ)U169 phoA glnV44 
φ80Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17] were also used 
for cloning and purchased from New England Biolabs (Ipswich, MA). 
4.2.2 Plasmid construction 
Genes containing M.SssI heterodimeric fragments have been described 
elsewhere [168](Chapter 3). Genes encoding zinc finger-fused M.SssI 
heterodimeric fragments were cloned into mammalian expression vector 
pBUDCE4.1. The C-terminal fragment zinc finger fusion gene was placed 
under the control of the CMV immediate-early promoter. The N-terminal 
fragment zinc finger fusion gene was placed under the control of the EF-
1α promoter. Oligonucleotides encoding the SV40-NLS and a FLAG-tag 
were annealed to their reverse complement sequence by incubating at 
over 95°C for over 2 minutes and cooling to room temperature. Annealed 
oligonucleotides contained overhangs complementary to cut sites at 
either the N-termini or C-termini of the zinc fingers. Double stranded 
DNA was phosphorylated and ligated to fuse these DNA sequences to 
zinc finger genes, creating the constructs shown in Figure 4.1B. 
The region between the origin of replication and CMV promoter was 
removed; we cloned various target sites in its place. These target sites 
were created by annealing complementary, phosphorylated 
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oligonucleotides as above. Oligonucleotides encoded the desired target 
site and, when annealed to each other, created double stranded 
sequences of DNA with overhangs complementary for restriction sites in 
the pBUD plasmid. This DNA was then ligated into pBUD plasmids. 
We modified the above plasmid with two BsmBI sites in order clone 
and test optimized variants that were identified through E. coli selections 
in Chapter 3. A gBlock of the CD54a-fused-C-terminal M.SssI fragment 
was designed; within this gBlock, two adjacent BsmBI sites separated by 
an internal sequence replaced the region encoding amino acids [297-
301]. This gBlock was then cloned into pBUD and replaced the zinc 
finger-fused-C-terminal M.SssI fragment in this vector. The internal 
sequence between the two BsmBI sites was later also altered to remove 
an unwanted DNA sequence. The final construct is shown in Figure 
4.1B. 
The above plasmid was used to construct optimized C-terminal 
constructs, following a golden gate procedure preformed essentially as 
described [170]. In order to insert novel DNA sequences in the region 
encoding wildtype residues 297-301, variant sequences were created by 
designing two complementary oligonucleotides, annealed as above. These 
oligonucleotides contained sequences encoding novel amino acids 
flanked by regions complementary to BsmBI cut sites in the plasmid. 
BsmBI sites were then placed outside of these complementary regions. 
Digestion of BsmBI in the presence of the plasmid, the annealed 
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oligonucleotides and T7 ligase allowed for the rapid creation of optimized 
C-terminal fragments into the pBUD mammalian vectors. These were 
transformed into E. coli and sequenced. 
4.2.3 Cell culture 
HEK293 cells (a gift from Jim Stivers’ lab) were grown in RPMI 1640 with 
glutamine (Cat #11875-093, Life Technologies, Carlsbad, CA) 
supplemented with 10% FBS (Hyclone Cat #SH30088.03, Thermo 
Scientific, Waltham, MA). RKO cells were obtained from the American 
Type Culture Collection (Manassas, VA). Cells were grown in Minimal 
Essential Media with Earles (E-MEM) balanced salts and glutamine 
(Cat#112-018-101, Quality Biologicals, Gaithersburg, MD) supplemented 
with 10% FBS. Cells were grown at 5% CO2 and at 37°C. Cells were split 
by washing with DPBS (Cat #14190-250, Life Technologies, Carlsbad, 
CA), adding 1-2 mL 0.25% Trypsin-EDTA Cat #25-053-Cl (MediaTech, 
Herndon, VA) and diluting in appropriate media. Cells were frozen by 
trypsinizing, diluting in complete media and adding 5% DMSO before 
storage o/n at -80°C. Cells were then transferred and stored in liquid 
nitrogen. 
4.2.4 Transfection into HEK293 and RKO cells 
Cells were transfected with Lipofectamine 2000 Transfection Reagent 
(Life Technologies, Carlsbad, CA). DNA used for transient transfections 
was isolated from E. coli cultured in low salt media at pH 7.5, 
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supplemented with 50 μg/ml zeocin (Life Technologies, Carlsbad, CA). 
Plasmid was isolated with the PureYield Plasmid Miniprep Sytem 
(Promega, Madison, WI) according to the large culture volume protocol. 
 The day before transfection, HEK293 cells were seeded into 6-well 
plates (6x10-5 cells/well) or 10 cm dishes (3x10-6 cells/dish) to achieve 
cultures of 90-95% confluency on the day of transfection. For 
transfections in 6-well plates, 5 μg of DNA was incubated in 625 μl Opti-
MEM media (Life Technologies, Carlsbad, CA) for five minutes and 
combined with 12.5 μl lipofectamine in 625 μl Opti-MEM, which was then 
incubated for at least 20 minutes at room temperature. RPMI complete 
media (RPMI+10% FBS) was removed and replaced with 1250 μl Opti-
MEM media. The DNA, lipofectamine/Opti-MEM solution was added to 
cells and incubated for 24 hours at 5% CO2 and 37°C. This protocol was 
scaled up six-fold for transfections in 10 cm plates. 
 For transient transfections of RKO cells, 5x10-4 cells/well were 
seeded into 6-well plates and grown for several days until they achieved 
40-60% confluency. A mixture of 2 μg of DNA in 100 μl of E-MEM was 
incubated for five minutes and mixed with 6 μl of lipofectamine in 100 μl 
of E-MEM. DNA in E-MEM was combined with lipofectamine in E-MEM 
and incubated at room temperature for over 20 minutes. Fresh complete 
media (E-MEM + 10% FBS) (0.8 μl) was added to each well before 
transfection. The DNA/lipofectamine/E-MEM mixture (200 μl) was added 
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to each well in a dropwise fashion and incubated for 24 hours at 5% CO2 
and 37°C.  
For both RKO and HEK293 cells, after a 24-hour incubation of the 
transfection reagent and DNA transfection mixture was replaced with 2 
ml of the appropriate complete media (per well of a 6-well plate). Media 
was replaced, if necessary, at 24-hour intervals and the cells were 
harvested 72 hours after the initial addition of the transfection reagent. 
4.2.5 Plasmid digestion assays 
Isolation of plasmid DNA was preformed essentially as described [178]. 
Briefly, for 6-well plates, cells were disrupted mechanically or with 
trypsin and washed several times in DPBS. Cells were spun at 1500xg, 
resuspended in residual DPBS and lysed by the addition of 250 μl Hirt 
lysis buffer (0.6% w/v SDS and 10 mM EDTA). After lysis at room 
temperature for 20 minutes, 100 μl of ice cold 5M NaCl was added and 
the mixture was incubated at 4°C overnight. The mixture was spun at 
14,000xg for 15 minutes. A phenol chloroform extraction and ethanol 
precipitation were preformed essentially as described [162]. 
Phenol:Chloroform extraction of the aqueous layer was preformed at least 
twice and mixtures were back extracted with TE buffer. Aqueous layers 
were combined and extracted with an equal volume of chloroform. The 
aqueous layer was supplemented with 40 mM MgCl2 and 2 μl pellet paint 
co-precipitant (EMD Millipore, Billerica, MA) per 500 μl of aqueous 
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solution. Three volumes of ethanol (-20°C) per one volume of aqueous 
layer was added and incubated overnight at -20°C. The solution was 
centrifuged at 14,000xg and at 0°C for 30 minutes or more. The pellet 
was washed once in 70% w/v ethanol and redissolved in water. The 
protocol was scaled 6x and slightly modified for larger 10 cm dish 
transfection experiments. 
 Isolated DNA was purified with a Zymo Clean and Concentrator-5 
columns essentially as recommended by the manufacturer. Depending 
on size of the transfection experiment (6-well or 10 cm dish), DNA was 
incubated with 5 or 15 units of Plasmid-Safe-ATP-Dependent DNAse 
(Epicentre, Madison, WI) and 5 or 15 μg of DNAse and protease free 
RNAse (ThermoScientific, Waltham, MA), supplemented with 1mM ATP 
and 1X Plasmid-Safe reaction buffer. Reactions were incubated for at 
least 1 hr at 37°C and heat killed at over 70°C for at least 20 minutes. 
Reactions were divided into three equal aliquots and incubated with 
SnaBI (2.5 units) supplemented with BSA, FspI (2.5 units), or no enzyme 
at 37°C for 1 hour. Digestions were analyzed on a 1.2% w/v agarose gel 
in TAE run at 90 volts for 40 minutes. Images were captured using a Gel 
Logic 112 Imaging System. 
4.2.6 Bisulfite sequencing  
RKO cells, transfected with plasmid DNA, were harvested 72 hours after 
transfection via trypsinization and washed in DPBS. Chromosomal DNA 
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was isolated using a Genomic DNA Extraction PureLink Kit (Life 
Technologies, Carlsbad, CA) per manufacturers instructions. Isolated 
DNA was treated with bisulfite DNA reagent using and EZ DNA 
Methylation-Gold Kit (Zymo Research, Irvine, CA). PfuTurbo Cx Hotstart 
DNA polymerase (Agilent Technologies, Santa Clara, CA) was used to 
amplify bisulfite converted DNA. Touch down PCR was used to amplify 
only the correct region associated with the ICAM1 promoter and was 
modified from [179]. An initial cycle of 95°C for 3 min was followed by a 
touchdown PCR (95°C for 1 min, annealing temperature for 1 minute, 
72°C for 1 minute). The annealing temperature started at 64°C and was 
dropped 2°C degrees after two cycles and then decreased 1°C after every 
other cycle until the annealing temperature reached 57°C. After the 
touchdown PCR, an additional 40 cycles were carried out with the 
parameters above and the annealing temperature of 56°C. 
 Amplified PCR products were purified, ligated into pDIMN plasmids 
and transformed into NEB5 alpha or NEB10 beta cells. Colony PCR 
identified colonies containing the insert and these colonies were sent for 
sequencing. The sense strand was amplified with primers 5’-TAG TGA 
GCG GCC GCT AAG TTG GAG AGG GAG GAT TTG A-3’ (Fw) and 5’-TAG 
TTT GAA TTC CAT AAA CAA CTA CCT AAA CAT ACA TAA CCT AAC C-
3’(Rev). The anti-sense strand was amplified with primers 5’-TGA GTG 
CGG CCG CAT AAA ATA AAC ACA ATA ACA ATC TCC ACT CTC-3’(Fw) 
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and 5’-TTG TAT GAA TTC AGG TTG TAA TTT TGA GTA GTA GAG GAG 
TTT AG-3’ (Rev). 
4.2.7 Cell lysis and western blot analysis 
At 72 hours after transfection, HEK293 cells in 6-well plates were 
washed in ice cold DPBS and lysed in 50 μl ice cold RIPA lysis buffer (per 
well) supplemented with 1X protease inhibitor cocktail P8340 (Sigma 
Aldrich, St. Louis, MO). Lysates were vortexed intermittently and 
incubated on ice for 30 minutes before the soluble fraction was recovered 
by centrifugation. A 26 μl aliquot of soluble fraction was mixed with 10 μl 
of 4x NuPage LDS Sample Buffer (Life Technologies, Carlsbad, CA) and 4 
μl DTT (0.5 M) and incubated at over 70°C for 10 minutes. Samples were 
loaded on a 4-12% bis-tris gel and run in MES running buffer 
supplemented with 500 μl NuPAGE Antioxidant (Life Technologies, 
Carlsbad, CA) at 190 volts for 40 minutes.  
 Proteins were transferred to PVDF membranes using a Trans-Blot 
SD Semi-Dry Electrophoretic Transfer Cell (Biorad, Hercules, CA) in 
transfer buffer (10 ml of 20X NuPAGE transfer buffer, 100 μl NuPAGE 
antioxidant, 10 ml methanol in 100 ml) at 15 V for 30 minutes. The 
membrane was incubated with anti-FLAG monoclonal antibody (cat 
#0420 Lifetein, South Plainfield, NJ) diluted 2000-fold in blocking buffer 
(5% w/v milk in TBST) overnight at 4°C. The membrane was washed 
several times in TBST and incubated at room temperature for 30 min 
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with a goat anti-mouse-HRP conjugate (cat#170-5047, Biorad, Hercules, 
CA) diluted 6000-fold in blocking buffer (0.4% w/v dry milk in TBST) in a 
SNAP I.D. system (Millipore, Billerica, MA). After washing the membrane 
in TBST, the membrane was developed using the Immun-Star WesternC 
Chemiluminescence Kit (Biorad, Hercules, CA). Images were taken using 
the Molecular Imager XRS Gel Doc system and analyzed with Quantity 
One software.  
4.3 Results and discussion 
4.3.1 Heterodimeric methyltransferase-fusion proteins target 
methylation toward specific sites and are expressed in 
HEK293 cells 
We first attempted to demonstrate that methyltransferase fragments can 
be expressed and can target methylation in HEK293 cells. Each zinc 
finger methyltransferase fusion protein was cloned under the control of a 
separate constitutive promoter in the pBUD plasmid (Fig. 4.1A). In these 
experiments, HS1 and HS2 zinc fingers were fused to N-terminal and C-
terminal M.SssI fragments as described in chapters 2 and 3. 
Additionally, sequences encoding the SV40 NLS and FLAG-tag were 
fused to the terminal ends of each zinc finger (Fig. 4.1B). Finally, we 
added a targeted CpG site, nested within an FspI restriction site and 
flanked by HS1 and HS2 recognition sequences, to the pBUD plasmid 
(Fig. 4.1C). Transient transfection of pBUD plasmid containing an 
unrelated gene, Haps59-EGFP fusion [180], demonstrated that under the 
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conditions used to transfect our methyltransferase variants, 75-80% of 
the Haps59-EGFP transfected cells were fluorescent 72 hours post-
transfection.   
  
Figure 4.1 Constructs for eukaryotic expression vectors A) The pBUD 
mammalian expression vector with relevant gene sequences, promoters, 
resistance marker, and origin of replication. B) A graphical representation of the 
zinc finger (orange) fused methyltransferase fragments (cyan). FLAG-tags 
(purple) and NLS-SV40 (red) sequences are attached to each zinc finger. Below 
the C-terminal fragment, an enlarged area illustrates changes made to amino 
acid residues 295-303. The ‘wildtype’ heterodimeric methyltransferase, a 
generic library variant, or a construct designed to enable golden gate cloning of 
optimized constructs are shown. Note that the amino acid numbering 
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corresponds to the monomeric wildtype M.SssI construct. C) A schematic of a 
zinc finger-fused heterodimeric methyltransferase binding to its’ target site. D) 
The target site for N-terminal and C-terminal heterodimeric methyltransferase 
fragments fused to CD54-31opt and CD54a, respectively. 
 The plasmids expressing methyltransferase fragments were 
isolated 72 hours after transfection. Transfected plasmids and non-
transfected plasmids were assayed for their sensitivity to endonucleases 
whose activity is blocked by CpG methylation. Similar to the E. coli 
expression tests in Chapter 3, the targeted CpG site is nested within an 
FspI site. A SnaBI restriction site present in the CMV-promoter is not 
flanked by these zinc finger binding recognition sequences and is 
considered a non-target site. Thus, nicked or supercoiled plasmid in FspI 
or SnaBI digestion lanes indicate methylation-dependent protection at 
the target or non-target sites, respectively.  
 
Figure 4.2 Restriction digest assays of the ‘wildtype’, optimized and 
inactive variants. Inactive variants lack the zinc finger-fused C-terminal 
fragment. Variants are digested with no enzyme, FspI or SnaBI. Panel 1 depicts 
plasmid DNA prior to transfection. In panel 2, plasmid DNA was recovered from 
transfected HEK293 cells. Top (nicked) and bottom (supercoiled) bands are 
indicative of methylation-dependent protection from endonuclease digestion. 
Pixels of control DNA and ladder were saturated. The image was inverted and 
image contrast proportionally altered to enable visualization of transfected 
plasmids.  
Results demonstrated that the plasmid DNA, prior to transfection, 
was sensitive to SnaBI and FspI digestion. This is expected because the 
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pBUD plasmid lacks promoters recognized by native E. coli transcription 
machinery; methyltransferase fragments, therefore, should not be 
actively expressed in the E. coli from which the plasmid DNA was 
prepared. However, plasmid DNA encoding ‘wildtype’ (i.e. no mutations to 
residues 297-301) methyltransferase fragments appear to be partially 
protected from digestion prior to transfection (as indicated by nicked 
DNA in Fig 4.2 panel 1). This may be due to low-level, leaky 
transcription, and subsequent non-specific methylation of these highly 
active methyltransferase fragments in E. coli. Regardless, the ratio of 
protected DNA to digested DNA was so low that this was not expected to 
alter the interpretation of the protection assays in transfected plasmids. 
Undigested, non-transfected plasmids were present in nicked and 
supercoiled forms. In this case, the high levels of nicked DNA may result 
from the isolation procedure or from the use of zeocin, a DNA damaging 
agent, as a selectable marker during preparation in E. coli [181]. 
For plasmid isolated from transfected cells, the ‘wild-type’ 
heterodimeric methyltransferase fusion protein (KFNSE in the region 
corresponding to 297-301) methylates equally at the target and non-
target site, as indicated by the increased presence of nicked DNA relative 
to linear DNA (Fig 4.2 panel 2). The lack of specificity for the target site 
over non-target site in HEK293 cells mirrors the lack of specificity 
observed in E. coli [168]. Similar to our in vivo E. coli experiments, in 
HEK293 cells, the optimized variant (residues CFESY in the region 
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corresponding to 297-301) appears only methylated at the target site. 
This result is indicated by the presence of nicked band in the FspI 
digested, but not the SnaBI digested lanes (Fig 4.2 panel 2). As expected, 
plasmid lacking one of the two obligate heterodimeric fragments shows 
no nicked or supercoiled DNA when digested with either FspI or SnaBI. 
However, unlike our results in E. coli, we observed large amount of 
unprotected plasmid DNA in our transfected ‘wildtype’ constructs. This 
may be due to inefficient transcription or translation of the 
methyltransferase fragments in our transfected cells. Further, incomplete 
methylation may also be due to a limited number of plasmids present in 
the nucleus compared to the cytoplasm [182].  
  
 
Figure 4.3 Western blot of transiently transfected HEK293 cells Lane 1: 
Empty pBUD.CE.4.1; lane 2: pBUD expressing zinc finger-fused N-terminal and 
C-terminal ‘wild type’ fragments; lane 3: pBUD expressing only the zinc finger-
fused N-terminal fragment; lane 4 pBUD expressing FLAG-EGFP-Haps59 
fusion; lane 5: empty; lane 6: MagicMark XP Western Protein Standard. 
To further demonstrate that both fragments were expressed in at 
least some population of HEK293 cells, transiently transfected cells were 
lysed 72 hours after transfection. A western blot of the lysates using 
anti-FLAG antibodies revealed that cells transfected with the ‘wildtype’ N-
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terminal and C-terminal methyltransferase-zinc finger fusion fragments 
produced two bands of the expected sizes (45 Kd and 25.8Kd 
respectively) (Fig. 4.3). Cells transfected with plasmid encoding only the 
N-terminal fragment expressed only one band (45Kd) of the expected size.  
4.3.2 ‘Wildtype’ heterodimeric zinc finger fusion proteins methylate 
chromosomal DNA. 
It would be significant to show that a heterodimeric methyltransferase is 
active on chromosomal DNA. Studies have shown that zinc fingers 
known to interact with plasmid DNA may not be able to access the same 
sequences within the chromosome due to the DNA’s inaccessibility 
within the chromatin structure [183].  
 To demonstrate that our heterodimeric, zinc finger-fused 
methyltransferases are active on the chromosome, we transfected pBUD 
plasmids containing zinc finger methyltransferase fusion proteins into 
RKO cells. In these experiments, the N-terminal construct was fused to 
CD54-31Opt and the C-terminal constructs were fused to CD54a (see 
Chapter 3). A target site with cognate zinc finger binding sequences 
flanking an internal AfeI site was also cloned into these vectors (Fig. 
4.1D). We used these constructs because they encode zinc fingers that, 
in E. coli, efficiently targeted methylation to a region of DNA matching 
one found in the promoter of the Intercellular Cell Adhesion Molecule 1 
(ICAM1) gene. Further, the promoter of ICAM1 was found to be 
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hypomethylated in RKO cells [184]. Preliminary bisulfite analysis 
confirmed this. 
 Bisulfite sequencing of the antisense strand (relative to the top 
strand in Fig. 4.2D) reliably covers 29 CpG sites. When we analyzed 8 
clones from bisulfite treated CFESY optimized variant, we observed one 
methylated site present in one of the 8 clones. This site was not the CpG 
site flanked by the zinc finger recognition sequences. When we assessed 
chromosome isolated from cells transected with the ‘wildtype variant,’ 4 
of 15 clones had methylation on at least two sites. One clone was 
methylated at 16 of the possible 29 sites assessed. Only one sequence 
appeared methylated at the target site. 
 The results are the first evidence to suggest that these 
heterodimeric methyltransferases methylate chromosomal DNA. The 
transfection efficiency was estimated qualitatively to be 30-40% based on 
the fluorescence observed in RKO cells transfected with a pBUD Haps59-
EGFP construct (the same conditions used to transfect the 
methyltransferase-containing constructs). Assuming the transfection 
efficiency of the active ‘wildtype’ methyltransferase construct is the same, 
then all successfully transfected cells showed some degree of 
methylation. 
 Given the level of activity observed in the plasmid digestion assays, 
one would expect to observe a higher level of methylation at the desired 
target site. This might be explained by a decrease in the accessibility of 
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chromosomal DNA at this site. A lack of observed methylation on the 
chromosomal target site for both the ‘wildtype’ and optimized variants 
might also be explained by the presence of the target site on the pBUD 
vector. In transfected cells, there would be many more equivalents of 
target site sequences on the plasmid than on the chromosome. Assuming 
the levels of activity are relatively low compared to E. coli assays, the 
plasmid’s target site would essentially mask any targeting ability of the 
methyltransferase. Alternatively, the methyltransferase may be 
methylating the target site on only the sense strand, rather than the 
antisense strand. A preference for one strand has been observed in our 
M.HhaI methyltransferase zinc finger fusion proteins [168]. Sequencing 
data of the sense strand however, was poor, due presumably to the 
highly repetitive sequences found on the bisulfite-converted sequence.  
 To test other variants, we used golden gate cloning to quickly 
construct mammalian expression vectors with optimized C-terminal 
constructs identified in chapter 3. We also removed the ICAM1 target site 
from these plasmids and replaced it with the site shown in Figure 4.1C. 
However, the transient transfection efficiency of these experiments was 




We demonstrate that both heterodimeric methyltransferase-zinc finger 
fusion proteins are expressed in HEK293 cells. Further, we provide the 
first evidence that these constructs bias methylation toward a desired 
target site in transiently transfected cells. In RKO cells, we demonstrate 
that very active variants methylate chromosomal DNA. More optimization 
is needed to increase the transfection efficiency and expression levels in 
RKO cells before any statements can be made about the ability of these 
constructs to target methylation on the chromosome. 
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5 Conclusions and future directions 
5.1 Introduction 
We have engineered targeted methyltransferases by fusing zinc fingers to 
various bifurcated methyltransferases [110,168]. Zinc finger recognition 
sequences flank a targeted CpG site; zinc finger binding events assist the 
reassembly of bifurcated methyltransferase fragments over this targeted 
CpG site. Targeted methylation is only possible when the bifurcated 
fragments are impaired in their innate ability to reassemble into a 
functional enzyme or in their innate affinity for DNA. Deletions to either 
the presumed fragment-fragment interface or mutations of residues 
responsible for innate DNA affinity have proven necessary to reduce the 
off-target methylation of our zinc finger-fused heterodimeric 
methyltransferases [110,168](Chapter 3).  
We have shown that several parameters affect the ability of the 
fragments to functionally reassemble at a target site and methylate DNA. 
Important factors include the length of the linkers connecting zinc 
fingers to their methyltransferase fragment partners as well as the DNA 
spacers between a targeted CpG site and zinc finger recognition 
sequences [110,168]. The topology of the fusion between the zinc finger 
protein and the methyltransferase fragment will also facilitate or impair 
enzymatic activity at a target site. We believe these factors affect 
observed methylation at a targeted CpG site because they alter how 
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fragments are oriented with respect to each other and DNA. Proper 
orientation, we believe, facilitates fragment reassembly and methylation 
at a targeted CpG site [110,168].  
Directed evolution provides a means to select for enzymes with a 
desired activity. We successfully devised a positive and negative selection 
scheme to couple the targeted methylation activity of engineered 
methyltransferases to the in vitro survival of the DNA encoding those 
enzymes. To select against off-target methylation, we utilized 
methylation-dependent restriction endonuclease, McrBC [171]. To select 
for methylation at a target site, we utilized an endonuclease, FspI, whose 
activity is blocked by methylation. 
Finally, we have provided initial evidence to suggest that these zinc 
finger-fused bifurcated methyltransferases function in mammalian cell 
lines. However, further work must be done to demonstrate that optimized 
constructs can target specific sequences within the chromosome. 
5.2 Directed evolution: selecting for enzymatic activity regulated 
by DNA sequence recognition of both zinc finger-binding events. 
Our heterodimeric constructs methylate at half sites. Methyltransferase 
activity is observed if a CpG site is flanked by only one of the zinc finger 
recognition sequences. We attribute this activity to the residual affinity of 
the fragments for each other and/or for DNA. However, the presence of 
two zinc finger cognate sites which flank a CpG site results in a 
synergistic effect on observed methylation [168]. In other words, the 
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additive effect observed at both half sites is less than the activity 
observed at an intact target site.  
 
Figure 5.1 Selecting for heterodimeric methyltransferases that require 
both zinc finger-binding events The selection is preformed as in chapter 3. (A) 
As in chapter 2 and 3, the vector encodes both heterodimeric fragments fused 
to zinc fingers under the control of separate, inducible arabinose (pBAD) and 
IPTG (lac) inducible promoters; the plasmid also contains an araC gene. The 
target site has been modified to contain two half sites flanking an intact target 
site; a larger representation is shown in Fig 5.1C. (B) The fate of different 
methylation patterns in our selection is shown. Unmethylated DNA is digested 
by FspI. DNA methylated at the target site is protected from FspI digestion but 
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is not a substrate for McrBC digestion. DNA methylated at the target site and 
half sites is protected from FspI digestion, but is a substrate for McrBC 
digestion. (C) A target site flanked on either side by two half sites is shown. The 
ideal zinc finger-fused heterodimeric methyltransferase methylates at the intact 
target site, but not the half sites. (D) A zinc finger-fused heterodimeric 
methyltransferase is shown that is not dependent on both zinc finger-cognate 
DNA sequence interactions. DNA is subject to McrBC digestion (represented by 
arrows). (E) An illustration demonstrates how the stringency of the selection 
against half-site activity may be increased by adding tandem half sites. 
Increasing the number of half sites increases the likelihood that two half sites 
may be methylated, resulting in subsequent DNA digestion by McrBC. 
By modifying the selection preformed in Chapter 3, it may be 
possible to engineer methyltransferases that are completely dependent 
upon both zinc finger protein-binding events. This may be accomplished 
by selecting against the activity at half sites. Figure 5.1 illustrates how 
modifications can be made to the selection scheme originally outlined in 
chapter 3. 
As in Figure 3.1, the intact target site contains both zinc finger 
recognition sequences that flank an internal CpG, which is itself nested 
within an FspI restriction site. However in Figure 5.1A, this target is 
further flanked by two half sites. Because McrBC endonuclease activity 
requires two CpG sites, activity occurring at the target site and either of 
the two half sites will result in endonuclease digestion of the plasmid. 
Plasmid encoding inactive methyltransferases will be digested with FspI. 
Methylation at the target site and only the target site will be protected 
from FspI and McrBC digestion (Fig. 5.1B). 
 Figure 5.1C and D illustrates the DNA sequence of these new sites 
demonstrating the activities of our ideal (C) or non-optimized (D) 
methyltransferase constructs. Finally, the stringency of the selection may 
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be increased by adding more half sites. Assuming the intact target site 
sequence is methylated, any other methylation event should result in the 
destruction of the plasmid DNA. 
5.3 Fusion of heterodimeric methyltransferase fragments to TAL 
effectors 
Zinc fingers have been used to create user-defined targeted 
methyltransferases, nucleases, and transcription factors. However, as 
noted in the introductory chapter, zinc finger motifs are not completely 
modular. Zinc finger motifs may bind DNA bases outside their three base 
pair registers [147]. Attempts at modular assembly of these motifs have 
high failure rates as assessed by bacterial two-hybrid assays [146]. 
Though not discussed in this thesis, we designed several other zinc finger 
methyltransferase fusion constructs that failed to methylate any CpG 
sites in vivo. Recently, zinc finger nucleases were shown to catalyze 
numerous off-target cleavage events in vitro and in cancer cell lines [124]. 
These recent reports speak to the limitations of zinc finger-mediated 
protein reassembly strategies. 
 TAL effectors (TALEs) motifs have been shown to be more modular 
than zinc finger motifs. Because a single motif binds to a single base, the 
design of TALEs with new binding specificity has also proven much 
simpler. Given the ease of design, it would be advantageous to use 
modular TALEs to construct targeted methyltransferases. Initial 
experiments not reported in this thesis demonstrated that TALE-
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methyltransferase fusion proteins were inactive. However, TALE variants 
that are expressed well in eukaryotic cells may not express well in E. coli 
(David R. Liu lab personal communication).  
TALEs may not be a panacea for those attempting to target specific 
DNA sequences. Repetitive addition of the same base-specific, repeat-
variable di-residues (RVDs) often fail to bind DNA, as assessed by a plant 
reporter assay [185]. Further, engineered TALEs may not be able to 
distinguish every base in every sequence context with equal efficiency 
[186]. RVDs, like zinc fingers, may not be perfectly modular. Further, 
several variables, including the sequence of non-repetitive TALE N-
terminal and C-terminal domains, the topology of the fusion constructs, 
linkers connecting domains, and base pair spacing may have to be re-
optimized to enable proper activity of TALE methyltransferases.  
5.4 Targeting methylation toward a human chromosome 
Our proof of principle studies demonstrate that targeted 
methyltransferases are expressed in HEK293 cells, methylate a targeted 
site on plasmid DNA in HEK293 cells, and will methylate chromosomal 
DNA in RKO cells. However, we have yet to show that optimized 
heterodimeric fragments will target a specific site within chromosomal 
DNA. 
 There are several complicating factors that must be overcome to 
enable one to target biologically relevant CpG sites. First, two multi-
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domain zinc finger proteins must be designed to target each CpG site. As 
discussed, zinc finger motifs do not exist for every three base-pair site 
and modular construction of known motifs may not always result in new 
zinc finger proteins capable of binding novel DNA sequences. The success 
of modular assembly in particular was shown to drastically decrease with 
the decrease in GNN sequences present in a target sequence [146]. Thus, 
certain sequences flanking a desired CpG site may not be amenable to 
zinc finger construction. However, zinc fingers need not always be 
designed de novo for every site. Many researchers have designed zinc 
fingers that bind to gene promoters (as reviewed in [187]). A literature 
search for a desired target may reveal previously constructed and 
characterized zinc fingers for a desired region. Such an approach 
identified CD54-31Opt (Chapters 3 and 4). 
 Secondly, the human cell line must be hypomethylated at the 
desired site. HEK293 cells are hypermethylated in the ICAM1 promoter 
(data not shown). Thus, these cells were not appropriate models for 
testing our designed ICAM1 targeting methyltransferases.  
Finally, the efficiency of transient transfection must be high 
enough to allow for adequate assessment of the targeted 
methyltransferase. Inefficient transfection may prevent the observation of 
the targeted methylation. Assuming the activity of optimized variants in 
mammalian cells is similar to that observed in E. coli (often 40-60% 
methylation at the target site), then a low (~10%) transfection efficiency 
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will result in 4-6% methylation at a targeted CpG site. Other groups have 
overcome this issue by co-transfecting with plasmids expressing LNGFR 
and GFP. Magnetic activated cell sorting can then be used to enrich for 
transfected cells and the percentage of enriched transiently transfected 
cells can then be assessed using fluorescence-activated cell sorting 
(FACS), creating a more accurate assessment of enzymatic activity [106].  
Finally, demonstrating site-specific methylation in human cell lines 
is complicated by the presence of endogenous human 
methyltransferases. Unless engineered constructs are transfected and 
assayed in DNMT knockouts, it will be difficult to assess whether 
observed methylation is a result of the engineered or endogenous 
enzymes. Observed off-target methylation around a targeted CpG site 
may result from the recruitment of endogenous cellular machinery to the 
original targeted methylated CpG site, encouraging the methylation of 
surrounding CpG sites. 
Assuming these criteria are met and constructs can successfully 
methylate a specific CpG site within the chromosome, a set of 
experiments could be designed to probe the effects of site-specific 
methylation. Quantitative PCR has been used to measure differences in 
expression caused by biased methyltransferases [105,106]. Chromatin 
immunoprecipitation of histone modifications might elucidate any 
epigenetic alterations caused by targeted methylation. Further, long term 
culture of transiently transfected constructs might allow one to assess 
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how aberrant epigenetic traits are corrected, maintained or spread over 
days and months. A similar experiment was recently performed to first 
target H3K9 methylation and then to observe the maintenance or loss of 









1. Kornberg A, Zimmerman SB, Kornberg SR, Josse J (1959) 
Enzymatic synthesis of deoxyribonucleic acid. Influence of 
bacteriophage T2 on the synthetic pathway in host cells. Proc Natl 
Acad Sci U S A 45: 772–785. 
2. Gold M, Hurwitz J, Anders M (1963) The enzymatic methylation of 
RNA and DNA. I. Biochem Biophys Res Commun 11: 107–114. 
doi:10.1016/0006-291X(63)90075-5. 
3. Gold M, Hurwitz J, Anders M (1963) The enzymatic methylation of 
RNA and DNA, II. On the species specificity of the methylation 
enzymes. Proc Natl Acad Sci U S A 50: 164-169. 
4. Arber W (1965) Host specificity of DNA produced by Escherichia 
coli. V. The role of methionine in the production of host specificity. 
J Mol Biol 11: 247–256. doi:10.1016/S0022-2836(65)80055-9. 
5. Kühnlein U, Linn S, Arber W (1969) Host specificity of DNA 
produced by Escherichia coli. XI. In vitro modification of phage fd 
replicative form. Proc Natl Acad Sci U S A 63: 556–562. 
6. Kühnlein U, Arber W (1972) Host specificity of DNA produced by 
Escherichia coli. XV. The role of nucleotide methylation in in vitro 
B-specific modification. J Mol Biol 63: 9–19. 
7. Wion D, Casadesús J (2006) N6-methyl-adenine: an epigenetic 
signal for DNA–protein interactions. Nat Rev Microbiol 4: 183–192. 
doi:10.1038/nrmicro1350. 
8. Roberts RJ, Vincze T, Posfai J, Macelis D (2009) REBASE--a 
database for DNA restriction and modification: enzymes, genes 
and genomes. Nucleic Acids Res 38: D234–D236. 
doi:10.1093/nar/gkp874. 
9. Cheng X (1995) Structure and function of DNA 
methyltransferases. Annu Rev Biophys Biomol Struct 24: 293–
318. doi:10.1146/annurev.bb.24.060195.001453. 
10. Smith HO (1979) Nucleotide sequence specificity of restriction 
endonucleases. Science 205: 455–462. 
11. Cheng X, Kumar S, Posfai J, Pflugrath JW, Roberts RJ (1993) 
 122 
Crystal structure of the HhaI DNA methyltransferase complexed 
with S-adenosyl-L-methionine. Cell 74: 299–307. 
12. Shieh F, Youngblood B, Reich NO (2006) The role of Arg165 
towards base flipping, base stabilization and catalysis in M.HhaI. 
J Mol Biol 362: 516–527. doi:10.1016/j.jmb.2006.07.030. 
13. Kumar S, Cheng X, Klimasauskas S, Mi S, Posfai J, et al. (1994) 
The DNA (cytosine-5) methyltransferases. Nucleic Acids Res 22: 1–
10. 
14. Posfai J, Bhagwat AS, Pósfai G, Roberts RJ (1989) Predictive 
motifs derived from cytosine methyltransferases. Nucleic Acids 
Res 17: 2421–2435. 
15. Sankpal UT, Rao DN (2002) Structure, function, and mechanism 
of HhaI DNA methyltransferases. Crit Rev Biochem Mol Biol 37: 
167–197. doi:10.1080/10409230290771492. 
16. Klimasauskas S, Kumar S, Roberts RJ, Cheng X (1994) HhaI 
methyltransferase flips its target base out of the DNA helix. Cell 
76: 357–369. 
17. Gerasimaite R, Merkiene E, Klimasauskas S (2011) Direct 
observation of cytosine flipping and covalent catalysis in a DNA 
methyltransferase. Nucleic Acids Res 39: 3771–3780. 
doi:10.1093/nar/gkq1329. 
18. Wu JC, Santi DV (1987) Kinetic and catalytic mechanism of HhaI 
methyltransferase. J Biol Chem 262: 4778–4786. 
19. Osterman DG, DePillis GD, Wu JC, Matsuda A, Santi DV (1988) 5-
Fluorocytosine in DNA is a mechanism-based inhibitor of HhaI 
methylase. Biochemistry 27: 5204–5210. 
20. Erlanson DA, Chen L, Verdine GL (1993) DNA methylation 
through a locally unpaired intermediate. J Am Chem Soc 115: 
12583–12584. doi:10.1021/ja00079a047. 
21. Chen L, MacMillan AM, Chang W, Ezaz-Nikpay K, Lane WS, et al. 
(1991) Direct identification of the active-site nucleophile in a DNA 
(cytosine-5)-methyltransferase. Biochemistry 30: 11018–11025. 
doi:10.1021/bi00110a002. 
22. Chen L, MacMillan A, Verdine GL (1993) Mutational separation of 
DNA binding from catalysis in a DNA cytosine methyltransferase. 
J Am Chem Soc 115: 5318–5319. 
 123 
23. Renbaum P, Abrahamove D, Fainsod A, Wilson GG, Rottem S, et 
al. (1990) Cloning, characterization, and expression in Escherichia 
coli of the gene coding for the CpG DNA methylase from 
Spiroplasma sp. strain MQ1(M.SssI). Nucleic Acids Res 18: 1145–
1152. doi:10.1093/nar/18.5.1145. 
24. Koudan E, Bujnicki J, Gromova E (2004) Homology modeling of 
the CG-specific DNA methyltransferase SssI and its complexes 
with DNA and AdoHcy. J Biomol Struct Dyn 22: 339–345. 
25. Darii MV, Kirsanova OV, Drutsa VL, Kochetkov SN, Gromova ES 
(2007) Isolation and site-directed mutagenesis of DNA 
methyltransferase SssI. Mol Biol 41: 110–117. 
doi:10.1134/S0026893307010153. 
26. Darii MV, Cherepanova NA, Subach OM, Kirsanova OV, Raskó T, 
et al. (2009) Mutational analysis of the CG recognizing DNA 
methyltransferase SssI: Insight into enzyme–DNA interactions. 
Biochim Biophys Acta 1794: 1654–1662. Available: 
http://linkinghub.elsevier.com/retrieve/pii/S1570963909001824
. 
27. Lauster R (1988) Duplication and variation as a phylogenetic 
principle of type-II DNA methyltransferases. Gene 74: 243. 
28. Lauster R (1989) Evolution of type II DNA methyltransferases. A 
gene duplication model. J Mol Biol 206: 313–321. 
29. Wilson GG (1992) Amino acid sequence arrangements of DNA-
methyltransferases. Methods Enzymol 216: 259–279. 
30. Malone T, Blumenthal RM, Cheng X (1995) Structure-guided 
analysis reveals nine sequence motifs conserved among DNA 
amino-methyltransferases, and suggests a catalytic mechanism 
for these enzymes. J Mol Biol 253: 618–632. 
doi:10.1006/jmbi.1995.0577. 
31. Choe W, Chandrasegaran S, Ostermeier M (2005) Protein fragment 
complementation in M.HhaI DNA methyltransferase. Biochem 
Biophys Res Commun 334: 1233–1240. 
doi:10.1016/j.bbrc.2005.07.017. 
32. Jeltsch A (1999) Circular permutations in the molecular evolution 
of DNA methyltransferases. J Mol Evol 49: 161–164. 
doi:10.1007/PL00006529. 
33. Bujnicki JM (2002) Sequence permutations in the molecular 
 124 
evolution of DNA methyltransferases. BMC Evol Biol 2: 3. 
34. Xu S, Xiao J, Posfai J, Maunus R, Benner J (1997) Cloning of the 
BssHII restriction-modification system in Escherichia coli : BssHII 
methyltransferase contains circularly permuted cytosine-5 
methyltransferase motifs. Nucleic Acids Res 25: 3991–3994. 
35. Karreman C, de Waard A (1990) Agmenellum quadruplicatum 
M.AquI, a novel modification methylase. J Bacteriol 172: 266–272. 
36. Pinarbasi H, Pinarbasi E, Hornby D (2002) Recombinant alpha 
and beta subunits of M.AquI constitute an active DNA 
methyltransferase. J Biochem Mol Biol 35: 348–351. 
37. Lee KF, Kam KM, Shaw PC (1995) A bacterial methyltransferase 
M.EcoHK311 requires two proteins for in vitro methylation. 
Nucleic Acids Res 23: 103–108. 
38. Jeltsch A, Kröger M, Pingoud A (1995) Evidence for an 
evolutionary relationship among type-II restriction endonucleases. 
Gene 160: 7–16. 
39. Olsen GJ, Woese CR, Overbeek R (1994) The winds of 
(evolutionary) change: breathing new life into microbiology. J 
Bacteriol 176: 1–6. 
40. Jeltsch A, Pingoud A (1996) Horizontal gene transfer contributes 
to the wide distribution and evolution of type II restriction-
modification systems. J Mol Evol 42: 91–96. 
doi:10.1007/BF02198833. 
41. Kobayashi I (2001) Behavior of restriction-modification systems as 
selfish mobile elements and their impact on genome evolution. 
Nucleic Acids Res 29: 3742–3756. doi:10.1093/nar/29.18.3742. 
42. Ponger L, Li W-H (2005) Evolutionary diversification of DNA 
methyltransferases in eukaryotic genomes. Mol Biol Evol 22: 
1119–1128. doi:10.1093/molbev/msi098. 
43. Colot V, Rossignol J-L (1999) Eukaryotic DNA methylation as an 
evolutionary device. Bioessays 21: 402–411. 
doi:10.1002/(SICI)1521-1878(199905)21:5<402::AID-
BIES7>3.0.CO;2-B. 
44. Jurkowski TP, Jeltsch A (2011) On the evolutionary origin of 
eukaryotic DNA methyltransferases and Dnmt2. PLoS ONE 6: 
e28104. doi:10.1371/journal.pone.0028104. 
 125 
45. Bestor TH (1988) Cloning of a mammalian DNA methyltransferase. 
Gene 74: 9–12. doi:10.1016/0378-1119(88)90238-7. 
46. Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X (2007) 
Structure of Dnmt3a bound to Dnmt3L suggests a model for de 
novo DNA methylation. Nature 449: 248–251. 
doi:10.1038/nature06146. 
47. Song J, Rechkoblit O, Bestor TH, Patel DJ (2011) Structure of 
DNMT1-DNA complex reveals a role for autoinhibition in 
maintenance DNA methylation. Science 331: 1036–1040. 
doi:10.1126/science.1195380. 
48. Gruenbaum Y, Cedar H, Razin A (1982) Substrate and sequence 
specificity of a eukaryotic DNA methylase. Nature 295: 620–622. 
doi:10.1038/295620a0. 
49. Leonhardt H, Page AW, Weier HU, Bestor TH (1992) A targeting 
sequence directs DNA methyltransferase to sites of DNA 
replication in mammalian nuclei. Cell 71: 865–873. 
50. Goyal R, Reinhardt R, Jeltsch A (2006) Accuracy of DNA 
methylation pattern preservation by the Dnmt1 methyltransferase. 
Nucleic Acids Res 34: 1182–1188. doi:10.1093/nar/gkl002. 
51. Mortusewicz O, Schermelleh L, Walter J, Cardoso MC, Leonhardt 
H (2005) Recruitment of DNA methyltransferase I to DNA repair 
sites. Proc Natl Acad Sci U S A 102: 8905–8909. 
doi:10.1073/pnas.0501034102. 
52. Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, et al. (1997) Human 
DNA-(cytosine-5) methyltransferase-PCNA complex as a target for 
p21WAF1. Science 277: 1996–2000. 
53. Sharif J, Muto M, Takebayashi S-I, Suetake I, Iwamatsu A, et al. 
(2007) The SRA protein Np95 mediates epigenetic inheritance by 
recruiting Dnmt1 to methylated DNA. Nature 450: 908–912. 
doi:10.1038/nature06397. 
54. Qin W, Leonhardt H, Pichler G (2011) Regulation of DNA 
methyltransferase 1 by interactions and modifications. Nucleus 2: 
392–402. doi:10.4161/nucl.2.5.17928. 
55. Okano M, Xie S, Li E (1998) Cloning and characterization of a 
family of novel mammalian DNA (cytosine-5) methyltransferases. 
Nat Genet 19: 219–220. doi:10.1038/890. 
 126 
56. Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases 
Dnmt3a and Dnmt3b are essential for de novo methylation and 
mammalian development. Cell 99: 247–257. 
57. Bourc'his D, Xu GL, Lin CS, Bollman B, Bestor TH (2001) Dnmt3L 
and the establishment of maternal genomic imprints. Science 294: 
2536–2539. doi:10.1126/science.1065848. 
58. Chedin F, Lieber MR, Hsieh C-L (2002) The DNA 
methyltransferase-like protein DNMT3L stimulates de novo 
methylation by Dnmt3a. Proc Natl Acad Sci U S A 99: 16916–
16921. doi:10.1073/pnas.262443999. 
59. Gowher H, Liebert K, Hermann A, Xu G, Jeltsch A (2005) 
Mechanism of stimulation of catalytic activity of Dnmt3A and 
Dnmt3B DNA-(cytosine-C5)-methyltransferases by Dnmt3L. J Biol 
Chem 280: 13341–13348. doi:10.1074/jbc.M413412200. 
60. Watanabe D, Suetake I, Tada T, Tajima S (2002) Stage- and cell-
specific expression of Dnmt3a and Dnmt3b during embryogenesis. 
Mech Dev 118: 187–190. doi:10.1016/S0925-4773(02)00242-3. 
61. Ooi SKT, Qiu C, Bernstein E, Li K, Jia D, et al. (2007) DNMT3L 
connects unmethylated lysine 4 of histone H3 to de novo 
methylation of DNA. Nature 448: 714–717. 
doi:10.1038/nature05987. 
62. Otani J, Nankumo T, Arita K, Inamoto S, Ariyoshi M, et al. (2009) 
Structural basis for recognition of H3K4 methylation status by the 
DNA methyltransferase 3A ATRX-DNMT3-DNMT3L domain. EMBO 
Rep 10: 1235–1241. doi:10.1038/embor.2009.218. 
63. Zhang Y, Jurkowska R, Soeroes S, Rajavelu A, Dhayalan A, et al. 
(2010) Chromatin methylation activity of Dnmt3a and Dnmt3a/3L 
is guided by interaction of the ADD domain with the histone H3 
tail. Nucleic Acids Res 38: 4246–4253. doi:10.1093/nar/gkq147. 
64. Dhayalan A, Rajavelu A, Rathert P, Tamas R, Jurkowska RZ, et al. 
(2010) The Dnmt3a PWWP domain reads histone 3 lysine 36 
trimethylation and guides DNA methylation. J Biol Chem 285: 
26114–26120. doi:10.1074/jbc.M109.089433. 
65. Cedar H, Bergman Y (2009) Linking DNA methylation and histone 
modification: patterns and paradigms. Nat Rev Genet 10: 295–
304. doi:10.1038/nrg2540. 
66. Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate 
 127 
genomes. J Mol Biol 196: 261–282. 
67. Deaton AM, Bird A (2011) CpG islands and the regulation of 
transcription. Genes Dev 25: 1010–1022. 
doi:10.1101/gad.2037511. 
68. Smith ZD, Meissner A (2013) DNA methylation: roles in 
mammalian development. Nat Rev Genet 14: 204–220. 
doi:doi:10.1038/nrg3354. 
69. Bergman Y, Cedar H (2013) DNA methylation dynamics in health 
and disease. Nat Struct Mol Biol 20: 274–281. 
doi:10.1038/nsmb.2518. 
70. Li E, Bestor TH, Jaenisch R (1992) Targeted mutation of the DNA 
methyltransferase gene results in embryonic lethality. Cell 69: 
915–926. 
71. Tsumura A, Hayakawa T, Kumaki Y, Takebayashi S-I, Sakaue M, 
et al. (2006) Maintenance of self-renewal ability of mouse 
embryonic stem cells in the absence of DNA methyltransferases 
Dnmt1, Dnmt3a and Dnmt3b. Genes Cells 11: 805–814. 
doi:10.1111/j.1365-2443.2006.00984.x. 
72. Robertson KD (2005) DNA methylation and human disease. Nat 
Rev Genet 6: 597–610. doi:10.1038/nrg1655. 
73. Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, et al. 
(1999) The DNMT3B DNA methyltransferase gene is mutated in 
the ICF immunodeficiency syndrome. Proc Natl Acad Sci U S A 96: 
14412–14417. 
74. Lawson C, Wolf S (2009) ICAM-1 signaling in endothelial cells. 
Pharmacol Rep 61: 22–32. 
75. Tachimori A, Yamada N, Sakate Y, Yashiro M, Maeda K, et al. 
(2005) Up regulation of ICAM-1 gene expression inhibits tumour 
growth and liver metastasis in colorectal carcinoma. Eur J Cancer 
41: 1802–1810. doi:10.1016/j.ejca.2005.04.036. 
76. Ogawa Y, Hirakawa K, Nakata B, Fujihara T, Sawada T, et al. 
(1998) Expression of intercellular adhesion molecule-1 in invasive 
breast cancer reflects low growth potential, negative lymph node 
involvement, and good prognosis. Clin Cancer Res 4: 31–36. 
77. Arnold JM, Cummings M, Purdie D, Chenevix-Trench G (2001) 
Reduced expression of intercellular adhesion molecule-1 in 
 128 
ovarian adenocarcinomas. Br J Cancer 85: 1351–1358. 
doi:10.1054/bjoc.2001.2075. 
78. Rosette C (2005) Role of ICAM1 in invasion of human breast 
cancer cells. Carcinogenesis 26: 943–950. 
doi:10.1093/carcin/bgi070. 
79. Sun JJ, Zhou XD, Liu YK, Tang ZY, Feng JX, et al. (1999) Invasion 
and metastasis of liver cancer: expression of intercellular adhesion 
molecule 1. J Cancer Res Clin Oncol 125: 28–34. 
doi:10.1007/s004320050238. 
80. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, 
Cheng JC, et al. (2005) Prognostic relevance of methylation 
markers in patients with non-muscle invasive bladder carcinoma. 
Eur J Cancer 41: 2769–2778. doi:10.1016/j.ejca.2005.07.019. 
81. Hellebrekers DMEI, Castermans K, Viré E, Dings RPM, Hoebers 
NTH, et al. (2006) Epigenetic regulation of tumor endothelial cell 
anergy: silencing of intercellular adhesion molecule-1 by histone 
modifications. Cancer Res 66: 10770–10777. doi:10.1158/0008-
5472.CAN-06-1609. 
82. Hellebrekers DMEI, Melotte V, Viré E, Langenkamp E, Molema G, 
et al. (2007) Identification of epigenetically silenced genes in tumor 
endothelial cells. Cancer Res 67: 4138–4148. doi:10.1158/0008-
5472.CAN-06-3032. 
83. de Groote ML, Kazemier HG, Huisman C, van der Gun BTF, Faas 
MM, et al. (2013) Upregulation of endogenous ICAM-1 reduces 
ovarian cancer cell growth in the absence of immune cells. Int J 
Cancer 134: 280–290. doi:10.1002/ijc.28375. 
84. Chen H, Kazemier HG, de Groote ML, Ruiters MHJ, Xu G-L, et al. 
(2013) Induced DNA demethylation by targeting Ten-Eleven 
Translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res 
[Epub ahead of print]: 1–12. doi:10.1093/nar/gkt1019. 
85. Wicki R, Franz C, Scholl FA, Heizmann CW, Schäfer BW (1997) 
Repression of the candidate tumor suppressor gene S100A2 in 
breast cancer is mediated by site-specific hypermethylation. Cell 
Calcium 22: 243–254. doi:10.1016/S0143-4160(97)90063-4. 
86. Zhang X, Wu M, Xiao H, Lee M-T, Levin L, et al. (2010) 
Methylation of a single intronic CpG mediates expression silencing 
of the PMP24 gene in prostate cancer. Prostate 70: 765–776. 
doi:10.1002/pros.21109. 
 129 
87. Renda M, Baglivo I, Burgess-Beusse B, Esposito S, Fattorusso R, 
et al. (2007) Critical DNA binding interactions of the insulator 
protein CTCF: a small number of zinc fingers mediate strong 
binding, and a single finger-DNA interaction controls binding at 
imprinted loci. J Biol Chem 282: 33336–33345. 
doi:10.1074/jbc.M706213200. 
88. Lukinavicius G, Lapinaite A, Urbanaviciute G, Gerasimaite R, 
Klimasauskas S (2012) Engineering the DNA cytosine-5 
methyltransferase reaction for sequence-specific labeling of DNA. 
Nucleic Acids Res 40: 11594–11602. doi:10.1093/nar/gks914. 
89. Balganesh TS, Reiners L, Lauster R, Noyer-Weidner M, Wilke K, et 
al. (1987) Construction and use of chimeric SPR/Φ3Τ DNA 
methyltransferases in the definition of sequence recognizing 
enzyme regions. EMBO J 6: 3543–3549. 
90. Klimasauskas S, Nelson JL, Roberts RJ (1991) The sequence 
specificity domain of cytosine-C5 methylases. Nucleic Acids Res 
19: 6183–6190. 
91. Gubler M, Braguglia D, Meyer J, Piekarowicz A, Bickle TA (1992) 
Recombination of constant and variable modules alters DNA 
sequence recognition by type IC restriction-modification enzymes. 
EMBO J 11: 233–240. 
92. Walter J, Trautner TA, Noyer-Weidner M (1992) High plasticity of 
multispecific DNA methyltransferases in the region carrying DNA 
target recognizing enzyme modules. EMBO J 11: 4445–4450. 
93. Lange C, Wild C, Trautner TA (1996) Identification of a subdomain 
within DNA-(cytosine-C5)-methyltransferases responsible for the 
recognition of the 5' part of their DNA target. EMBO J 15: 1443–
1450. 
94. Cohen HM, Tawfik DS, Griffiths AD (2002) Promiscuous 
methylation of non-canonical DNA sites by HaeIII 
methyltransferase. Nucleic Acids Res 30: 3880–3885. 
doi:10.1093/nar/gkf507. 
95. Cohen HM, Tawfik DS, Griffiths AD (2004) Altering the sequence 
specificity of HaeIII methyltransferase by directed evolution using 
in vitro compartmentalization. Protein Eng Des Sel 17: 3–11. 
doi:10.1093/protein/gzh001. 
96. Tímár E, Groma G, Kiss A, Venetianer P (2004) Changing the 
recognition specificity of a DNA-methyltransferase by in vitro 
 130 
evolution. Nucleic Acids Res 32: 3898–3903. 
doi:10.1093/nar/gkh724. 
97. Gerasimaite R, Vilkaitis G, Klimasauskas S (2009) A directed 
evolution design of a GCG-specific DNA hemimethylase. Nucleic 
Acids Res 37: 7332–7341. doi:10.1093/nar/gkp772. 
98. Rockah-Shmuel L, Tawfik DS (2012) Evolutionary transitions to 
new DNA methyltransferases through target site expansion and 
shrinkage. Nucleic Acids Res 40: 11627–11637. 
doi:10.1093/nar/gks944. 
99. Xu GL, Bestor TH (1997) Cytosine methylation targetted to pre-
determined sequences. Nat Genet 17: 376–378. 
doi:10.1038/ng1297-376. 
100. McNamara AR, Hurd PJ, Smith AEF, Ford KG (2002) 
Characterisation of site-biased DNA methyltransferases: 
specificity, affinity and subsite relationships. Nucleic Acids Res 
30: 3818–3830. 
101. Carvin CD, Parr RD, Kladde MP (2003) Site-selective in vivo 
targeting of cytosine-5 DNA methylation by zinc-finger proteins. 
Nucleic Acids Res 31: 6493–6501. 
102. Carvin CD, Dhasarathy A, Friesenhahn LB, Jessen WJ, Kladde MP 
(2003) Targeted cytosine methylation for in vivo detection of 
protein-DNA interactions. Proc Natl Acad Sci U S A 100: 7743–
7748. doi:10.1073/pnas.1332672100. 
103. Li F, Papworth M, Minczuk M, Rohde C, Zhang Y, et al. (2007) 
Chimeric DNA methyltransferases target DNA methylation to 
specific DNA sequences and repress expression of target genes. 
Nucleic Acids Res 35: 100–112. doi:10.1093/nar/gkl1035. 
104. van der Gun BTF, Maluszynska-Hoffman M, Kiss A, Arendzen AJ, 
Ruiters MHJ, et al. (2010) Targeted DNA methylation by a DNA 
methyltransferase coupled to a triple helix forming oligonucleotide 
to down-regulate the epithelial cell adhesion molecule. Bioconjug 
Chem 21: 1239–1245. doi:10.1021/bc1000388. 
105. Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, et al. 
(2012) Epigenetic reprogramming of cancer cells via targeted DNA 
methylation. Epigenetics 7: 350–360. doi:10.4161/epi.19507. 
106. Siddique AN, Nunna S, Rajavelu A, Zhang Y, Jurkowska RZ, et al. 
(2013) Targeted methylation and gene silencing of VEGF-A in 
 131 
human cells by using a designed Dnmt3a-Dnmt3L single-chain 
fusion protein with increased DNA methylation activity. J Mol Biol 
425: 479–491. doi:10.1016/j.jmb.2012.11.038. 
107. de Groote ML, Verschure PJ, Rots MG (2012) Epigenetic Editing: 
targeted rewriting of epigenetic marks to modulate expression of 
selected target genes. Nucleic Acids Res 40: 10596–10613. 
doi:10.1093/nar/gks863. 
108. Nomura W, Barbas CF (2007) In vivo site-specific DNA 
methylation with a designed sequence-enabled DNA methylase. J 
Am Chem Soc 129: 8676–8677. doi:10.1021/ja0705588. 
109. Meister GE, Chandrasegaran S, Ostermeier M (2008) An 
engineered split M.HhaI-zinc finger fusion lacks the intended 
methyltransferase specificity. Biochem Biophys Res Commun 377: 
226–230. doi:10.1016/j.bbrc.2008.09.099. 
110. Meister GE, Chandrasegaran S, Ostermeier M (2010) 
Heterodimeric DNA methyltransferases as a platform for creating 
designer zinc finger methyltransferases for targeted DNA 
methylation in cells. Nucleic Acids Res 38: 1749–1759. 
doi:10.1093/nar/gkp1126. 
111. Pósfai G, Kim SC, Szilák L, Kovács A, Venetianer P (1991) 
Complementation by detached parts of GGCC-specific DNA 
methyltransferases. Nucleic Acids Res 19: 4843–4847. 
112. Ślaska-Kiss K, Tímár E, Kiss A (2012) Complementation between 
inactive fragments of SssI DNA methyltransferase. BMC Mol Biol 
13: 17. doi:10.1186/1471-2199-13-17. 
113. Pelletier JN, Campbell-Valois FX, Michnick SW (1998) 
Oligomerization domain-directed reassembly of active 
dihydrofolate reductase from rationally designed fragments. Proc 
Natl Acad Sci U S A 95: 12141–12146. 
doi:10.1073/pnas.95.21.12141. 
114. Paschon DE, Ostermeier M (2004) Construction of protein 
fragment complementation libraries using incremental truncation. 
Methods Enzymol 388: 103–116. doi:10.1016/S0076-
6879(04)88010-8. 
115. Morell M, Ventura S, Avilés FX (2009) Protein complementation 
assays: approaches for the in vivo analysis of protein interactions. 
FEBS Lett 583: 1684–1691. doi:10.1016/j.febslet.2009.03.002. 
 132 
116. Paschon DE, Patel ZS, Ostermeier M (2005) Enhanced catalytic 
efficiency of aminoglycoside phosphotransferase (3 ')-IIa achieved 
through protein fragmentation and reassembly. J Mol Biol 353: 
26–37. doi:10.1016/j.jmb.2005.08.026. 
117. Kim YG, Cha J, Chandrasegaran S (1996) Hybrid restriction 
enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl 
Acad Sci U S A 93: 1156–1160. 
118. Li L, Wu LP, Chandrasegaran S (1992) Functional domains in Fok 
I restriction endonuclease. Proc Natl Acad Sci U S A 89: 4275–
4279. 
119. Bitinaite J, Wah DA, Aggarwal AK, Schildkraut I (1998) FokI 
dimerization is required for DNA cleavage. Proc Natl Acad Sci U S 
A 95: 10570–10575. 
120. Carroll D (2011) Genome engineering with zinc-finger nucleases. 
Genetics 188: 773–782. doi:10.1534/genetics.111.131433. 
121. Joung JK, Sander JD (2013) TALENs: a widely applicable 
technology for targeted genome editing. Nat Rev Mol Cell Biol 14: 
49–55. doi:10.1038/nrm3486. 
122. Alwin S, Gere MB, Guhl E, Effertz K, Barbas CF, et al. (2005) 
Custom zinc-finger nucleases for use in human cells. Mol Ther 12: 
610–617. doi:10.1016/j.ymthe.2005.06.094. 
123. Pruett-Miller SM, Connelly JP, Maeder ML, Joung JK, Porteus MH 
(2008) Comparison of zinc finger nucleases for use in gene 
targeting in mammalian cells. Mol Ther 16: 707–717. 
doi:10.1038/mt.2008.20. 
124. Pattanayak V, Ramirez CL, Joung JK, Liu DR (2011) Revealing off-
target cleavage specificities of zinc-finger nucleases by in vitro 
selection. Nat Methods 8: 765–770. doi:10.1038/nmeth.1670. 
125. Szczepek M, Brondani V, Büchel J, Serrano L, Segal DJ, et al. 
(2007) Structure-based redesign of the dimerization interface 
reduces the toxicity of zinc-finger nucleases. Nat Biotechnol 25: 
786–793. doi:10.1038/nbt1317. 
126. Miller JC, Holmes MC, Wang J, Guschin DY, Lee Y-L, et al. (2007) 
An improved zinc-finger nuclease architecture for highly specific 
genome editing. Nat Biotechnol 25: 778–785. 
doi:10.1038/nbt1319. 
 133 
127. Doyon Y, Vo TD, Mendel MC, Greenberg SG, Wang J, et al. (2011) 
Enhancing zinc-finger-nuclease activity with improved obligate 
heterodimeric architectures. Nat Methods 8: 74–79. 
doi:doi:10.1038/nmeth.1539. 
128. Ramalingam S, Kandavelou K, Rajenderan R, Chandrasegaran S 
(2011) Creating designed zinc-finger nucleases with minimal 
cytotoxicity. J Mol Biol 405: 630–641. 
doi:10.1016/j.jmb.2010.10.043. 
129. Cornu TI, Thibodeau-Beganny S, Guhl E, Alwin S, Eichtinger M, 
et al. (2008) DNA-binding specificity is a major determinant of the 
activity and toxicity of zinc-finger nucleases. Mol Ther 16: 352–
358. doi:10.1038/sj.mt.6300357. 
130. Händel E-M, Alwin S, Cathomen T (2009) Expanding or restricting 
the target site repertoire of zinc-finger nucleases: the inter-domain 
linker as a major determinant of target site selectivity. Mol Ther 
17: 104–111. doi:10.1038/mt.2008.233. 
131. Elrod-Erickson M, Rould MA, Nekludova L, Pabo CO (1996) Zif268 
protein-DNA complex refined at 1.6 angstrom: A model system for 
understanding zinc finger-DNA interactions. Structure 4: 1171–
1180. doi:10.1016/S0969-2126(96)00125-6. 
132. Miller J, McLachlan AD, Klug A (1985) Repetitive zinc-binding 
domains in the protein transcription factor IIIA from Xenopus 
oocytes. EMBO J 4: 1609–1614. 
133. Iuchi S (2001) Three classes of C2H2 zinc finger proteins. Cell Mol 
Life Sci 58: 625–635. 
134. Pavletich NP, Pabo CO (1991) Zinc finger-DNA recognition: crystal 
structure of a Zif268-DNA complex at 2.1 A. Science 252: 809–
817. 
135. Pabo CO, Peisach E, Grant RA (2001) Design and selection of 
novel Cys2His2 zinc finger proteins. Annu Rev Biochem 70: 313–
340. doi:10.1146/annurev.biochem.70.1.313. 
136. Choo Y, Klug A (1994) Selection of DNA binding sites for zinc 
fingers using rationally randomized DNA reveals coded 
interactions. Proc Natl Acad Sci U S A 91: 11168–11172. 
137. Rebar EJ, Pabo CO (1994) Zinc finger phage: affinity selection of 
fingers with new DNA-binding specificities. Science 263: 671–673. 
doi:10.1126/science.8303274. 
 134 
138. Jamieson AC, Kim SH, Wells JA (1994) In vitro selection of zinc 
fingers with altered DNA-binding specificity. Biochemistry 33: 
5689–5695. 
139. Segal DJ, Dreier B, Beerli RR, Barbas CF (1999) Toward 
controlling gene expression at will: Selection and design of zinc 
finger domains recognizing each of the 5“-GNN-3” DNA target 
sequences. Proc Natl Acad Sci U S A 96: 2758–2763. 
doi:10.1073/pnas.96.6.2758. 
140. Dreier B, Segal DJ, Barbas CF III (2000) Insights into the 
molecular recognition of the 5′-GNN-3′ family of DNA sequences by 
zinc finger domains. J Mol Biol 303: 489–502. 
doi:10.1006/jmbi.2000.4133. 
141. Dreier B, Beerli RR, Segal DJ, Flippin JD, Barbas CF (2001) 
Development of zinc finger domains for recognition of the 5“-ANN-
3” family of DNA sequences and their use in the construction of 
artificial transcription factors. J Biol Chem 276: 29466–29478. 
doi:10.1074/jbc.M102604200. 
142. Dreier B, Fuller RP, Segal DJ, Lund CV, Blancafort P, et al. (2005) 
Development of zinc finger domains for recognition of the 5“-CNN-
3” family DNA sequences and their use in the construction of 
artificial transcription factors. J Biol Chem 280: 35588–35597. 
doi:10.1074/jbc.M506654200. 
143. Blancafort P, Magnenat L, Barbas CF (2003) Scanning the human 
genome with combinatorial transcription factor libraries. Nat 
Biotechnol 21: 269–274. doi:10.1038/nbt794. 
144. Sander JD, Zaback P, Joung JK, Voytas DF, Dobbs D (2007) Zinc 
Finger Targeter (ZiFiT): an engineered zinc finger/target site 
design tool. Nucleic Acids Res 35: W599–W605. 
doi:10.1093/nar/gkm349. 
145. Mandell JG, Barbas CF (2006) Zinc Finger Tools: custom DNA-
binding domains for transcription factors and nucleases. Nucleic 
Acids Res 34: W516–W523. doi:10.1093/nar/gkl209. 
146. Ramirez CL, Foley JE, Wright DA, Müller-Lerch F, Rahman SH, et 
al. (2008) Unexpected failure rates for modular assembly of 
engineered zinc fingers. Nat Methods 5: 374–375. 
doi:10.1038/nmeth0508-374. 
147. Isalan M, Choo Y, Klug A (1997) Synergy between adjacent zinc 
fingers in sequence-specific DNA recognition. Proc Natl Acad Sci U 
 135 
S A 94: 5617–5621. 
148. Hurt JA, Thibodeau SA, Hirsh AS, Pabo CO, Joung JK (2003) 
Highly specific zinc finger proteins obtained by directed domain 
shuffling and cell-based selection. Proc Natl Acad Sci U S A 100: 
12271–12276. doi:10.1073/pnas.2135381100. 
149. Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony 
RM, et al. (2008) Rapid “open-source” engineering of customized 
zinc-finger nucleases for highly efficient gene modification. Mol 
Cell 31: 294–301. doi:10.1016/j.molcel.2008.06.016. 
150. Maeder ML, Thibodeau-Beganny S, Sander JD, Voytas DF, Joung 
JK (2009) Oligomerized pool engineering (OPEN): an “open-source” 
protocol for making customized zinc-finger arrays. Nat Protoc 4: 
1471–1501. doi:10.1038/nprot.2009.98. 
151. Sander JD, Dahlborg EJ, Goodwin MJ, Cade L, Zhang F, et al. 
(2011) Selection-free zinc-finger-nuclease engineering by context-
dependent assembly (CoDA). Nat Methods 8: 67–69. 
doi:10.1038/nmeth.1542. 
152. Moscou MJ, Bogdanove AJ (2009) A Simple Cipher Governs DNA 
Recognition by TAL Effectors. Science 326: 1501–1501. 
doi:10.1126/science.1178817. 
153. Scholze H, Boch J (2010) TAL effector-DNA specificity. Virulence 
1: 428–432. doi:10.4161/viru.1.5.12863. 
154. Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, et al. (2009) 
Breaking the Code of DNA Binding Specificity of TAL-Type III 
Effectors. Science 326: 1509–1512. doi:10.1126/science.1178811. 
155. Smith AE, Hurd PJ, Bannister AJ, Kouzarides T, Ford KG (2008) 
Heritable gene repression through the action of a directed DNA 
methyltransferase at a chromosomal locus. J Biol Chem 283: 
9878–9885. doi:10.1074/jbc.M710393200. 
156. Minczuk M, Papworth MA, Kolasinska P, Murphy MP, Klug A 
(2006) Sequence-specific modification of mitochondrial DNA using 
a chimeric zinc finger methylase. Proc Natl Acad Sci U S A 103: 
19689–19694. doi:10.1073/pnas.0609502103. 
157. Michnick SW, Remy I, Campbell-Valois FX, Vallée-Bélisle A, 
Pelletier JN (2000) Detection of protein-protein interactions by 
protein fragment complementation strategies. Methods Enzymol 
328: 208–230. 
 136 
158. Vlahovicek K, Pongor S (2000) Model.it: building three 
dimensional DNA models from sequence data. Bioinformatics 16: 
1044–1045. doi:10.1093/bioinformatics/16.11.1044. 
159. Qian B, Raman S, Das R, Bradley P, McCoy AJ, et al. (2007) High-
resolution structure prediction and the crystallographic phase 
problem. Nature 450: 259–264. doi:10.1038/nature06249. 
160. Wang C, Bradley P, Baker D (2007) Protein-protein docking with 
backbone flexibility. J Mol Biol 373: 503–519. 
doi:10.1016/j.jmb.2007.07.050. 
161. Mandell DJ, Coutsias EA, Kortemme T (2009) Sub-angstrom 
accuracy in protein loop reconstruction by robotics-inspired 
conformational sampling. Nat Methods 6: 551–552. 
doi:10.1038/nmeth0809-551. 
162. Sambrook J, Russell D (2001.) Molecular Cloning: A Laboratory 
Manual. 3rd ed. Argentine J, Irwin N, Janssen KA, Curtis S, 
Zierler M, et al., editors Cold Spring Harbor, NY: Cold Spring 
Harbor Laboratory Press. 722; 5.4–5.17; 8.21–8.22 pp. 
163. Beerli RR, Segal DJ, Dreier B, Barbas CF (1998) Toward 
controlling gene expression at will: specific regulation of the erbB-
2/HER-2 promoter by using polydactyl zinc finger proteins 
constructed from modular building blocks. Proc Natl Acad Sci U S 
A 95: 14628–14633. 
164. Nelson M, McClelland, M (1989) Effect of site-specific methylation 
on DNA modification methyltransferases and restriction 
endonucleases. Nucleic Acids Res 17: r389-r415. 
165. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, 
et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 
23: 2947–2948. doi:10.1093/bioinformatics/btm404. 
166. Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, et al. 
(2010) A new bioinformatics analysis tools framework at EMBL-
EBI. Nucleic Acids Res 38: W695–W699. 
doi:10.1093/nar/gkq313. 
167. Horsthemke B, Buiting K (2008) Genomic imprinting and 
imprinting defects in humans. Adv Genet 61: 225–246. 
doi:10.1016/S0065-2660(07)00008-9. 
168. Chaikind B, Kilambi KP, Gray JJ, Ostermeier M (2012) Targeted 
DNA methylation using an artificially bisected M.HhaI fused to 
 137 
zinc fingers. PLoS ONE 7: e44852. 
doi:10.1371/journal.pone.0044852. 
169. Firnberg E, Ostermeier M (2012) PFunkel: efficient, expansive, 
user-defined mutagenesis. PLoS ONE 7: e52031. 
doi:10.1371/journal.pone.0052031. 
170. Sanjana NE, Cong L, Zhou Y, Cunniff MM, Feng G, et al. (2012) A 
transcription activator-like effector toolbox for genome 
engineering. Nat Protoc 7: 171–192. doi:10.1038/nprot.2011.431. 
171. Sutherland E, Coe L, Raleigh EA (1992) McrBC: a multisubunit 
GTP-dependent restriction endonuclease. J Mol Biol 225: 327–
348. doi:10.1016/0022-2836(92)90925-A. 
172. Dryden DT, Murray NE, Rao DN (2001) Nucleoside triphosphate-
dependent restriction enzymes. Nucleic Acids Res 29: 3728–3741. 
doi:10.1093/nar/29.18.3728. 
173. Stewart FJF, Raleigh EAE (1998) Dependence of McrBC cleavage 
on distance between recognition elements. Biol Chem 379: 611–
616. 
174. Renbaum P, Razin A (1992) Mode of action of the Spiroplasma 
CpG methylase M.SssI. FEBS Lett 313: 243–247. 
175. Schneider TD, Stephens RM (1990) Sequence logos: a new way to 
display consensus sequences. Nucleic Acids Res 18: 6097–6100. 
176. Crooks GE, Hon G, Chandonia J-M, Brenner SE (2004) WebLogo: 
a sequence logo generator. Genome Res 14: 1188–1190. 
doi:10.1101/gr.849004. 
177. Magnenat L, Blancafort P, Barbas CF (2004) In vivo selection of 
combinatorial libraries and designed affinity maturation of 
polydactyl zinc finger transcription factors for ICAM-1 provides 
new insights into gene regulation. J Mol Biol 341: 635–649. 
doi:10.1016/j.jmb.2004.06.030. 
178. Hirt B (1967) Selective extraction of polyoma DNA from infected 
mouse cell cultures. J Mol Biol 26: 365–369. 
179. Jolly CJ, Neuberger MS (2001) Somatic hypermutation of 
immunoglobulin kappa transgenes: Association of mutability with 
demethylation. Immunol Cell Biol 79: 18–22. doi:10.1046/j.1440-
1711.2001.00968.x. 
 138 
180. Wright CM, Wright RC, Eshleman JR, Ostermeier M (2011) A 
protein therapeutic modality founded on molecular regulation. 
Proc Natl Acad Sci U S A 108: 16206–16211. 
doi:10.1073/pnas.1102803108. 
181. Oliva-Trastoy M, Trastoy MO, Defais M, Larminat F (2005) 
Resistance to the antibiotic Zeocin by stable expression of the Sh 
ble gene does not fully suppress Zeocin-induced DNA cleavage in 
human cells. Mutagenesis 20: 111–114. 
doi:10.1093/mutage/gei016. 
182. Lechardeur D, Lukacs GL (2006) Nucleocytoplasmic transport of 
plasmid DNA: a perilous journey from the cytoplasm to the 
nucleus. Hum Gene Ther 17: 882–889. 
doi:10.1089/hum.2006.17.882. 
183. Zhang L, Spratt SK, Liu Q, Johnstone B, Qi H, et al. (2000) 
Synthetic zinc finger transcription factor action at an endogenous 
chromosomal site. Activation of the human erythropoietin gene. J 
Biol Chem 275: 33850–33860. doi:10.1074/jbc.M005341200. 
184. Easwaran HP, Van Neste L, Cope L, Sen S, Mohammad HP, et al. 
(2010) Aberrant silencing of cancer-related genes by CpG 
hypermethylation occurs independently of their spatial 
organization in the nucleus. Cancer Res 70: 8015–8024. 
doi:10.1158/0008-5472.CAN-10-0765. 
185. Streubel J, Blücher C, Landgraf A, Boch J (2012) TAL effector 
RVD specificities and efficiencies. Nat Biotechnol 30: 593–595. 
doi:10.1038/nbt.2304. 
186. Meckler JF, Bhakta MS, Kim M-S, Ovadia R, Habrian CH, et al. 
(2013) Quantitative analysis of TALE-DNA interactions suggests 
polarity effects. Nucleic Acids Res 41: 4118–4128. 
doi:10.1093/nar/gkt085. 
187. Sera T (2009) Zinc-finger-based artificial transcription factors and 
their applications. Adv Drug Deliv Rev 61: 513–526. 
doi:10.1016/j.addr.2009.03.012. 
188. Hathaway NA, Bell O, Hodges C, Miller EL, Neel DS, et al. (2012) 









PhD: Chemical Biology 









Johns Hopkins University-Chemistry-Biology Interface Program…......…..2008-2014 
Baltimore, MD 
 PhD candidate degree expected in Winter 2014  
 Masters in Chemical Biology obtained June 2010 
 
Northwestern University……………………………………………………………......2003-2007     
Evanston, IL                                                                                                                                      
 Bachelor of Arts in Environmental Science, Minor in Chemistry 
 Cumulative GPA: 3.80 
 Cum Laude 
 Departmental Honors 





Protein Engineering Laboratory-Dr. Marc Ostermeier…………………..……..2008-2014 
Johns Hopkins University, Baltimore, MD 
 Rational design of zinc finger targeted methyltransferase proteins 
 Developed novel selection strategy for the directed evolution of targeted 
methyltransferases 
 Worked on proof of principle studies testing engineered methyltransferases in 
human cell lines 
 Responsible for training graduate and undergraduate students 
 
Marine Natural Products Laboratory-Dr. William Gerwick……………...…….2007-2008 
Scripps Institution of Oceanography, San Diego, CA 
 Employed as a Staff Research Associate II 
 Responsible for extracting and fractionating algal samples 
 Responsible for training laboratory volunteers 
 
Analytical Laboratory Course…....……………………………………………………………2007 
Northwestern University, Evanston, IL 
 Trained to use and interpret HPLC and GC-MS equipment; trained in the theory of 
chromatography.  
 
Natural Products Laboratory-Dr. Lyndon West ………………………………………….2006 
University of Georgia, Athens, GA 
 141 
 Awarded Northwestern’s Undergraduate Research Grant to create a quantitative 
analysis of natural products under Dr. Lyndon West.  In this facility, I became 
proficient with HPLC, NMR, and UV spec. equipment. 
 Collected samples while scuba diving and snorkeling 
 
Plant Systematics Course.....................................................................................2006 
Northwestern University, Evanston, IL 
 Trained to identify and collect plant species. 
 
Biology laboratory for genetics, biochemistry, and molecular biology……2005-2006 
Northwestern University, Evanston, IL 
 Trained to plate and grow bacteria using sterile techniques, used affinity  
chromatography to purify chimeric proteins 
  
Independent Research-Dr. Richard Silverman’s Group……....…………........2004-2005 
Northwestern University, Evanston, IL 
 Synthesized selective nNOS inhibitors, ran butyl lithium reactions, trained to run 
NMR spectrometers, experienced with column chromatography 
 
Organic Synthesis Lab Course for Chemistry Majors…………………………………..2004 
Northwestern University, Evanston, IL 
 Successfully designed a procedure to oxidize a benzylaldehyde using green 
chemistry,  
trained to interpret H-NMR, C-NMR, GC/MS, and FT-IR, trained to use FT-IR 
equipment 
    
Organic Chemistry Lab…………………………………………………………............2003-2004 
Northwestern University, Evanston, IL 
 Trained in basic synthesis techniques, synthesized N,N Diethyl-m-toulamide 





Chaikind, B., Ostermeier, M. “Directed evolution of improved zinc finger 
methyltransferases” [submitted] 
 
Chaikind, B., Kilambi, K. P., Gray, J. J. & Ostermeier, M. “Targeted DNA 
Methylation Using an Artificially Bisected M.HhaI Fused to Zinc Fingers.” PLoS ONE 




B. Chaikind, K. Praneeth Kilambi, J.J. Gray, and M. Ostermeier. “Targeted DNA 
Methylation Using a Bisected M.Hhal Fused to Zinc Fingers.” AIChe Annual Meeting 
(Talk). Pittsburgh, PA. October 29, 2012 
 
B. Chaikind and M. Ostermeier. "Toward a Site-Specific CpG Methyltransferase" 
(Poster). Gordon Research 
Conference. Epigenetics: Mechanisms, Development and Disease. Stonehill College, 
Easton, MA. August 9, 2011. 
 
 142 
B. Chaikind. “Solving the Supply Side Problem of Marine Natural Product 
Chemistry: A Directed Approach” (Poster). Chicago Undergraduate Research 




Editorial Assistant- Journal of Natural Products…………………………………2007-2008 
Scripps Institution of Oceanography, La Jolla, CA 
 Worked under Dr. William Gerwick to assist with the editorial process 
 
Shedd Aquarium Workshop Reporting….....……………………………………………….2007 
Shedd Aquarium, Chicago, IL                                               
 Compiled a white paper based on the Shedd Workshop  “Managing Cetaceans for 
Optimal Health.”  The workshop brought together an interdisciplinary group of 




 Voted by faculty to give only student lecture at Johns Hopkins Chemistry-Biology 
Interface Symposium-Fall 2012 
 Award for best poster Johns Hopkins University Chemistry-Biology Interface 
Symposium- Fall 2011 
 Honorable Mention National Science Foundation Graduate Research Fellowship 
Program 
 Northwestern Undergraduate Research Grant-studying natural products chemistry 
in University of Georgia 
 Deans List (3.7 GPA or higher) 7 out of 11 possible quarters at Northwestern 
University 
 Invited to apply to Northwestern Medical School’s accelerated 7 year program  
 
 
